<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0012.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0014.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h99" class="calibre7"></a><a id="page_8-1" class="calibre7"></a><a href="part0002.html#rh110" class="calibre7">APPROACH TO RHEUMATIC DISEASE</a></h2>
<p class="h2a">Approach to patient with joint pain</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Articular</b> vs. <b class="calibre4">periarticular</b> (bursitis, tendinitis) source of pain: typically active ROM more painful than passive ROM in periarticular process</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inflammatory</b> vs. <b class="calibre4">noninflammatory</b> pain: <i class="calibre3">features of inflammatory pain</i> include swelling, warmth or redness in specific joint, prolonged morning stiffness (&gt;30 min), improvement of pain/stiffness w/ motion/exercise. Assess for extra-articular features.</p>
<p class="bl"><span class="sbl">•</span> Physical exam: localize complaint, identify objective signs of inflammation, and assess number and pattern of affected joints</p>
<p class="bl"><span class="sbl">•</span> The physical exam is only <i class="calibre3">50–70% sensitive</i> for detecting inflammatory arthritis</p>
<p class="imagef"><img src="../images/00121.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><sup class="calibre35">a</sup>May initially present as arthralgia w/o overt arthritis. <sup class="calibre35">b</sup>Range of motion of joint or joint a/w bursa or tendon.</p>
<p class="capf"><b class="calibre4">Figure 8-1</b> Approach to arthritis</p>
<p class="image"><img src="../images/00122.jpeg" alt="" class="calibre2"/></p>
<p class="imagef"><img src="../images/00123.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*WBC count of aspirated fluid in septic bursitis often &lt; WBC count in septic arthritis.</p>
<p class="h2a">Radiologic features of major arthritides</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">OA:</b> plain films: asym joint space narrowing (JSN), <b class="calibre4">osteophytes</b>, subchondral sclerosis &amp; cysts; subchondral “gull-wing” erosions may be seen in less-common erosive OA; MRI may show early disease not seen on plain films; U/S ≈ MRI for structural damage ⊖</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RA:</b> plain films: symmetric JSN, early = periarticular <b class="calibre4">osteopenia;</b> late = marginal <b class="calibre4">erosions</b>; subluxations; MRI &amp; U/S can detect early and subclinical disease; MRI ≈ U/S for erosions</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Gout:</b> plain films: early = nonspec swelling; late = <b class="calibre4">tophus</b>, joint erosions w/ overhanging edges; U/S for detection of microtophi (double-contour sign); dual-energy CT (DECT): identify articular/periarticular UrA deposits vs. calcium deposits; MRI ≈ U/S for erosions</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spondyloarthritis:</b> e/o <b class="calibre4">sacroiliitis</b>: plain films: early = pseudo-widening SI joint space, late = sclerosis, erosions, <b class="calibre4">ankylosis;</b> SI MRI ↑ Se for early Δ; U/S ≈ MRI to detect enthesitis</p>
<p class="image1"><a id="page_8-2" class="calibre1"></a><img src="../images/00124.jpeg" alt="" class="calibre2"/></p>
<p class="h">I<small class="calibre30">NFLAMMATORY</small> M<small class="calibre30">ARKER</small> &amp; A<small class="calibre30">UTOANTIBODY</small> T<small class="calibre30">ESTING</small></p>
<p class="h2a">Inflammatory markers <span class="s">(<i class="calibre3">Mod Rheumatol</i> 2009;19:469)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ESR:</b> <i class="calibre3">indirect</i> measure of inflammation [↑ RBC aggregation due to acute-phase proteins (fibrinogen &amp; Ig) in blood]; slow to rise; may ↑ w/ age, preg., anemia, obesity. Ddx for &gt;100: malig. esp. MM, lymphoma; GCA or other vasculitis; ESRD; endocarditis, TB, osteo.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CRP:</b> <i class="calibre3">direct</i> measure of inflammation (protein produced by liver, part of innate immune system); <i class="calibre3">typically rises and falls before the ESR</i> w/ treatment/resolution of process</p>
<p class="h2a">Autoantibody testing <span class="s">(<i class="calibre3">Best Pract Res Clin Rheumatol</i> 2014;28:907)</span></p>
<p class="bl"><span class="sbl">•</span> ANA (anti-nuclear Ab): <i class="calibre3">screening test</i> for Ab directed against nuclear proteins; found in autoimmune conditions; most useful in testing for suspected connective tissue diseases</p>
<p class="bl"><span class="sbl">•</span> Order ANA only when <i class="calibre3">clinical suspicion for CTD</i> b/c nonspecific: 1:40 (very low ⊕, 25–30% of healthy Pts); 1:80 (low ⊕, 10–15% of healthy Pts); ≥1:160 (⊕, 5% of healthy Pts). May be ⊕ in Pts prior to clin manifest <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:1526; <i class="calibre3">Arthritis Res Ther</i> 2011;13:1)</span>.</p>
<p class="bl"><span class="sbl">•</span> If ANA ⊕ and high clinical suspicion for CTD, consider testing for Ab against dsDNA, Smith, Ro/La, RNP, Scl-70 and myositis-specific Abs <span class="s1r">(<i class="calibre3">highly specific</i> for various CTD)</span></p>
<p class="bl"><span class="sbl">•</span> ANA does <i class="calibre3">not</i> correlate well w/ disease activity, ∴ no clinical value in serial testing</p>
<p class="bl"><span class="sbl">•</span> “False ⊕” ANA: AIH, PBC, thyroid disease, certain infxns and malignancies, IBD, IPF</p>
<p class="bl"><span class="sbl">•</span> RF and anti-CCP (see “Rheumatoid Arthritis”)</p>
<p class="h">D<small class="calibre30">DX</small> &amp; A<small class="calibre30">PPROACH</small> <small class="calibre30">TO</small> C<small class="calibre30">OMMON</small> I<small class="calibre30">NPATIENT</small> R<small class="calibre30">HEUM</small> P<small class="calibre30">RESENTATIONS</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre36"/>
<col class="calibre27"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead">Presentation</p></td>
<td class="bg1-b"><p class="tabhead">Rheum Ddx</p></td>
<td class="bg1-b"><p class="tabhead">Rheum Lab Workup</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Fever of unknown origin</p></td>
<td class="bg0-br"><p class="tab">GCA/PMR, adult-onset Still’s, SLE, inflammatory arthritis, Takayasu’s, PAN, ANCA ⊕ vasc, cryo, HSP</p></td>
<td class="bg0-b"><p class="tab">ESR, CRP, ANA,</p>
<p class="tab">RF, ANCA, ± cryo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Pulmonary hypertension</p></td>
<td class="bg0-br"><p class="tab">Scleroderma (limited &gt; diffuse), MCTD, SLE, PM/DM (less common)</p></td>
<td class="bg0-b"><p class="tab">ANA, Scl-70, centromere, RNA Pol III, RNP</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Diff alveolar hemorrhage</p></td>
<td class="bg0-br"><p class="tab">ANCA ⊕ vasculitis,</p>
<p class="tab">Goodpasture’s, SLE, APS</p></td>
<td class="bg0-b"><p class="tab">ANCA, GBM, ANA, C3/C4</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Interstitial lung disease</p></td>
<td class="bg0-br"><p class="tab">Scleroderma (diffuse &gt; limited), sarcoid, RA, DM/PM, antisynthetase syndrome, Sjögren’s, MCTD, SLE (esp. pleura),</p>
<p class="tab">ANCA ⊕ vasc (esp. MPA)</p></td>
<td class="bg0-b"><p class="tab">ANA, Scl-70, RF/anti-CCP, CK, aldolase, ± myositis specific Abs, Jo-1, Ro/La, ANCA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Pleuro- pericarditis</p></td>
<td class="bg0-br"><p class="tab">SLE, RA, MCTD, DM/PM,</p>
<p class="tab">ANCA ⊕ vasc, Sjögren’s, PAN</p></td>
<td class="bg0-b"><p class="tab">ANA, dsDNA, Sm, RNP, Ro/La, RF, anti-CCP, ANCA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Acute kidney injury (+active sed. or s/s c/w CTD)</p></td>
<td class="bg0-br"><p class="tab">SLE (GN or nephrotic), ANCA ⊕ vasc (GN), scleroderma renal crisis (diffuse), Sjögren’s (RTA/TIN), PAN (infarct), HSP, Goodpasture’s (GN), cryo, APS</p></td>
<td class="bg0-b"><p class="tab">ANA, dsDNA, Smith, Ro/La, RNP, C3/C4, Scl-70 &amp;</p>
<p class="tab">RNA Pol III (SRC), ANCA,</p>
<p class="tab">GBM, cryos, APS panel</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neuropathy</p></td>
<td class="bg0-r"><p class="tab">ANCA ⊕ vasc, SLE, RA, PAN, Sjögren’s, cryo, sarcoid</p></td>
<td class="bg"><p class="tab">ANA, Ro/La, ANCA, cryo RF/anti-CCP, HCV, HBV</p></td>
</tr>
</table>
<h2 class="ct"><a id="h100" class="calibre7"></a><a id="page_8-3" class="calibre7"></a><a href="part0002.html#rh111" class="calibre7">RHEUMATOID ARTHRITIS (RA)</a></h2>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">Lancet</i> 2016;388:2023)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic, symmetric, debilitating, and destructive inflammatory polyarthritis characterized by proliferative synovial tissue (pannus) formation in affected joints</p>
<p class="bl"><span class="sbl">•</span> Pathogenesis involves over-production of TNF, IL-1, and IL-6 (∴ used as drug targets)</p>
<p class="bl"><span class="sbl">•</span> Risk stems from combination of genetic (~50% of risk), environmental influences (eg, smoking, silica dust), and Pt factors (periodontal disease, Δs in gut microbiome)</p>
<p class="bl"><span class="sbl">•</span> HLA-DRB1 haplotype a/w disease suscept., severity, &amp; response to Rx (<small class="calibre40">JAMA</small> 2015;313:1645)</p>
<p class="bl"><span class="sbl">•</span> Prevalence = 1% adults and 5% of ♀ &gt;70 y; ♀ to ♂ ratio = 3:1; peak incidence 50–75 y</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Medicine</i> 2010;38:167)</span></p>
<p class="bl"><span class="sbl">•</span> Usually insidious onset <b class="calibre4">pain</b>, <b class="calibre4">swelling</b>, &amp; impaired function of joints w/ prolonged <b class="calibre4">morning stiffness</b> for ≥6 wk (typically PIPs, MCPs, wrists, knees, ankles, MTPs, cervical spine)</p>
<p class="bl"><span class="sbl">•</span> Typically polyarticular (60% small joints, 30% large joints, 10% both), may be monoarticular (knee, shoulder, wrist) early in course; rheumatoid joints more susceptible to infection</p>
<p class="bl"><span class="sbl">•</span> Joint deformities: <b class="calibre4">ulnar deviation</b>, <b class="calibre4">swan neck</b> (MCP flexion, PIP hyperextension, DIP flexion), <b class="calibre4">boutonnière</b> (PIP flexion, DIP hyperextension), <b class="calibre4">cock-up deformities</b> (toes)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">C1–C2 instability</b> → myelopathy, ∴✔ C-spine flex/ext films prior to elective intubation</p>
<p class="bl"><span class="sbl">•</span> Constitutional symptoms: <i class="calibre3">low-grade</i> fever, weight loss, malaise</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Extra-articular manifestations</b> (18–41% of Pts) can occur at any time; ↑ frequency in seropositive (⊕ RF or anti-CCP) and with active disease <span class="s1r">(<i class="calibre3">Autoimmun Rev</i> 2011;11:123)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre42"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Extra-Articular Manifestations (EAMs)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Skin</p></td>
<td class="bg0-b"><p class="tabh">Rheumatoid nodules (20–30%, usually sero ⊕): extensor surface, bursae; can be in lung, heart, sclera</p>
<p class="tab">Raynaud’s, pyoderma gangrenosum, cutan. vasculitis (ulcers, purpura, etc.)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Pulm</p></td>
<td class="bg0-b"><p class="tab">ILD, airway disease, pleuritis, effusions (low glc), nodules, pulm HTN; precedes joint sx in 20% of cases; RA med toxicity (MTX, ? anti-TNF &amp; anti- CD20) <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Curr Opin Pulm</i></span> <span class="tfont1"><i class="calibre3">Med</i></span> <span class="tfont1">20</span><span class="tfont1">11</span><span class="tfont1">;362:367)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">CV</p></td>
<td class="bg0-b"><p class="tab">Accel. athero w/ ↑ risk of MI &amp; CV death, pericarditis (effusions in ⅓ of</p>
<p class="tab">sero ⊕), myocarditis, AF, coronary/systemic vasculitis. <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Arth Rheum</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;67:23</span><span class="tfont1">11</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Nervous</p></td>
<td class="bg0-b"><p class="tab">Mono/polyneuritis multiplex, CNS vasculitis, stroke, nerve entrapment</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Ocular</p></td>
<td class="bg0-b"><p class="tab">Scleritis, episcleritis, keratoconjunctivitis sicca (2° Sjögren’s)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Heme</p></td>
<td class="bg0-b"><p class="tab">Anemia of chronic disease, neutropenia (Felty’s syndrome: 1%, typically long- standing RA + splenomegaly; large granular lymphocyte leukemia: bone marrow infiltrated w/ lymphocytes ± myeloid hypoplasia), NHL, amyloidosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">Renal</p></td>
<td class="bg0-b"><p class="tab">Glomerulonephritis (usually mesangial), nephrotic syndrome (2° amyloidosis), nephrotoxicity from RA meds</p></td>
</tr>
<tr class="calibre12">
<td class="bg3-r"><p class="tab">Vasculitis</p></td>
<td class="bg"><p class="tab">Small &amp; medium vessels (usually ↑ RF titer, long-standing RA); pericarditis, ulcers, scleritis, &amp; neuropathy most common <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Curr Opin Rheum</i></span> <span class="tfont1">2009;2</span><span class="tfont1">1</span><span class="tfont1">:35)</span></p></td>
</tr>
</table>
<p class="h2a">Laboratory &amp; radiologic studies <span class="s">(<i class="calibre3">JAMA</i> 2018;320:1360)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RF</b> (IgM/IgA/IgG anti-IgGAb) ⊕ in ~70% of Pts w/ RA; also seen in other rheumatic diseases (SLE, Sjögren’s), infection (SBE, hepatitis, TB), cryo, ~5% of healthy population</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anti-CCP</b> (Ab to cyclic citrullinated peptide): ⊕ in ~80% of Pts w/ RA, similar Se (~70%), but more Sp (&gt;90%) than RF particularly for early RA <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2009;61:1472)</span>; a/w increased joint damage and low remission rates</p>
<p class="bl"><span class="sbl">•</span> ~20% are seronegative (RF <i class="calibre3"><span class="underline">and</span></i> anti-CCP negative)</p>
<p class="bl"><span class="sbl">•</span> ↑ ESR/CRP but nl in ~30%; ⊕ ANA in ~40%; ↑ globulin during periods of active disease</p>
<p class="bl"><span class="sbl">•</span> Radiographs of hands and wrists: periarticular osteopenia, bone erosions, joint subluxation</p>
<p class="bl"><span class="sbl">•</span> Increasing use of MSK U/S to diagnosis synovitis and erosive disease</p>
<p class="h2a">ACR/EULAR classification criteria <span class="s">(<i class="calibre3">Arth Rheum</i> 2010;62:2569)</span></p>
<p class="bl"><span class="sbl">•</span> Used in clinical research, but not in clinical practice</p>
<p class="bl"><span class="sbl">•</span> Relevant for Pts with ≥1 joint with synovitis not better explained by another disease</p>
<p class="bl"><span class="sbl">•</span> Likelihood of RA ↑ w/ higher # (espec. ≥4) of small joints involved, ⊕ RF or anti-CCP (espec. high titer), ANA, ↑ ESR or CRP, and duration ≥6 wk</p>
<p class="h2a">Management <span class="s">(<i class="calibre3">Lancet</i> 2017;389:2328 &amp; 2338; <i class="calibre3">JAMA</i> 2018;320:1360)</span></p>
<p class="bl"><span class="sbl">•</span> Early dx and Rx (esp DMARD) w/ frequent follow-up and escalation of Rx as needed with <b class="calibre4">goal to achieve clinical remission</b> or low disease activity</p>
<p class="bl"><span class="sbl">•</span> ↓ time to remission ≈ ↑ length of sustained remission <span class="s1r">(<i class="calibre3">Arthritis Res Ther</i> 2010;12:R97)</span></p>
<p class="bl"><span class="sbl">•</span> Sero-⊕ disease (eg, RF or anti-CCP) a/w aggressive joint disease &amp; EAM</p>
<p class="bl"><span class="sbl">•</span> At dx, start <i class="calibre3">both</i> rapid-acting agent (to acutely ↓ inflammation) and <b class="calibre4">D</b>isease<b class="calibre4">-M</b>odifying <b class="calibre4">A</b>nti<b class="calibre4">-R</b>heumatic <b class="calibre4">D</b>rug <b class="calibre4">(DMARD)</b> (typically take 1–3 mo to have max effect)</p>
<p class="bl"><a id="page_8-4" class="calibre1"></a><span class="sbl">•</span> <i class="calibre3">Rapid-acting drugs:</i></p>
<p class="bl1"><b class="calibre4">NSAIDs</b> or COX-2 inhibitors: ↑ CV risk, GI adverse events, AKI; consider starting w/ PPI</p>
<p class="bl1"><b class="calibre4">glucocorticoids</b>: low dose (&lt;20 mg/d oral) or joint injection</p>
<p class="bl1">NSAIDs + glucocorticoids: ↑↑ GI events; give PPI and minimize long-term concurrent use</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">DMARDs (see RA therapeutics below):</i></p>
<p class="bl1"><b class="calibre4">Methotrexate</b> (1<sup class="calibre15">st</sup> line unless CKD, hepatitis, EtOH or lung disease), alternatives include sulfasalazine or leflunomide; consider HCQ if seronegative and mild disease</p>
<p class="bl1">If inadequate response after 3 mo (despite DMARD dose escalation) consider:</p>
<p class="bl2"><b class="calibre4">combination Rx</b> w/ other DMARDs (eg, “triple therapy” w/ MTX, SAS and HCQ) <i class="calibre3">or</i></p>
<p class="bl2"><b class="calibre4">adding biologic</b> (anti-TNF typically 1<sup class="calibre15">st</sup> line unless contraindication)</p>
<p class="bl2">MTX/SAS/HCQ non-inferior to etanercept/MTX <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:307)</span></p>
<p class="bl2">JAK inhib: if fail biologics vs. initial DMARD <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:652; <i class="calibre3">Lancet</i> 2018;391:2503 &amp; 2513)</span></p>
<p class="bl"><span class="sbl">•</span> Given ↑ r/o early CV morbidity/mortality, try to ↓ risk w/ lifestyle mgmt, lipid &amp; DM screening</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre17"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">RA Therapeutics</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Arth Rheum</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">6;68:</span><span class="tfont1">1</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Class</p></td>
<td class="bg0-br"><p class="tabhead">Drug</p></td>
<td class="bg0-b"><p class="tabhead">Side Effects</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Traditional DMARDs</b></p></td>
<td class="bg0-br"><p class="tab">Methotrexate (MTX)</p>
<p class="tab">Leflunomide</p>
<p class="tab">Sulfasalazine (SAS)</p></td>
<td class="bg0-b"><p class="tabh">MTX: GI distress, stomatitis, ILD, myelosuppression, hepatotoxicity</p>
<p class="tab">Supplement MTX ± SAS w/ folate</p>
<p class="tab">✔ <i class="calibre3">G6PD prior to SAS</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Biologic DMARDs</b></p>
<p class="tab">(all anti-TNF ≈ efficacy; if inadequate resp to anti- TNF try non- TNF)</p></td>
<td class="bg0-br"><p class="tabh">Anti-TNF: etanercept, infliximab, adali- mumab, certolizumab, golimumab</p>
<p class="tab">CTLA4-Ig: abatacept</p>
<p class="tabh">Anti-IL-6R Ab: tocilizumab (studied as mono-Rx w/o MTX); sarilumab</p>
<p class="tab">Anti-CD20: rituximab</p>
<p class="tab">Anti-IL-1R: anakinra</p>
<p class="tab"><b class="calibre4"><i class="calibre3">Never use 2 biologics together</i></b></p></td>
<td class="bg0-b"><p class="tab">↑ risk bacterial/fungal/viral infxn</p>
<p class="tab">✔ TB, Hep B/C before starting</p>
<p class="tabh">Immunize against Zoster + Pneumococcus</p>
<p class="tabh">Anti-TNF: ? risk for CHF &amp; CNS demyelinating disease</p>
<p class="tab">Anti-IL-6R: risk of GI perf.</p>
<p class="tab">Rituximab: infusion reaction</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Other</b></p></td>
<td class="bg0-r"><p class="tab">Hydroxychloroquine (HCQ)</p>
<p class="tabh">JAK inhib: tofacitinib (TF), baricitinib, others</p>
<p class="tabh">Rarely: cyclosporine, azathioprine, gold</p></td>
<td class="bg"><p class="tab">HCQ: retinopathy, rash</p>
<p class="tab">JAK inhib: infxn, ↑ Cr, ↑ LFTs, HTN</p>
<p class="tabh">CsA: nephrotox, HTN, gum hyperplasia</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Lancet</i> 2013;381:451,918, &amp; 1541; <i class="calibre3">NEJM</i> 2012;367:495 &amp; 508, &amp; 369:307; <i class="calibre3">JAMA</i> 2016;316:1172)</p>
<h2 class="ct"><a id="h101" class="calibre7"></a><a href="part0002.html#rh112" class="calibre7">ADULT-ONSET STILL’S DISEASE &amp; RELAPSING POLYCHONDRITIS</a></h2>
<p class="h2a">Adult-onset Still’s disease <span class="s">(<i class="calibre3">J Rheumatol</i> 1992;19:424; <i class="calibre3">Autoimmun Rev</i> 2014;13:708)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rare autoinflammatory synd;</b> ♂ = ♀ w/ typical onset 16–35 y; sx evolve over wks to mos</p>
<p class="bl"><span class="sbl">•</span> Dx if 5 criteria are present &amp; ≥2 major; exclude infxn, malig, other rheumatic, drug rxn</p>
<p class="bl1"><b class="calibre4">Major:</b> fever ≥39°C for ≥1 wk (usually daily or twice daily high-spiking fever); arthralgias/arthritis ≥2 wk; Still’s rash (qv); ↑ WBC w/ 80% PMN</p>
<p class="bl1"><b class="calibre4">Minor:</b> sore throat; LAN; HSM; ↑ AST/ALT/LDH; negative ANA &amp; RF</p>
<p class="bl"><span class="sbl">•</span> Still’s rash (&gt;85%): nonpruritic macular or maculopapular salmon-colored rash; usually trunk or extremities; may be precipitated by trauma (Koebner phenomenon), warm water</p>
<p class="bl"><span class="sbl">•</span> Plain films: soft tissue swelling (<i class="calibre3">early</i>) → cartilage loss, erosions, carpal ankylosis (<i class="calibre3">late</i>)</p>
<p class="bl"><span class="sbl">•</span> Treatment: NSAIDs; steroids; steroid-sparing (MTX, <b class="calibre4">anakinra</b>, anti-TNF, <b class="calibre4">tocilizumab</b>)</p>
<p class="bl"><span class="sbl">•</span> Variable clinical course: 20% w/ long-term remission; 30% remit-relapse; ~50% chronic (esp. arthritis); ↑ risk of macrophage activation syndrome (life threatening)</p>
<p class="h2a">Relapsing polychondritis <span class="s">(<i class="calibre3">Rheum Dis Clin NA</i> 2013;39:263)</span></p>
<p class="bl"><span class="sbl">•</span> Inflammatory destruction of cartilaginous structures; onset usually age 40–60 y, ♂ = ♀</p>
<p class="bl"><span class="sbl">•</span> Subacute onset of <b class="calibre4">red</b>, <b class="calibre4">painful</b>, and <b class="calibre4">swollen cartilage;</b> ultimately atrophic &amp; deformed</p>
<p class="bl"><span class="sbl">•</span> Common clinical features: bilateral auricular chondritis; nonerosive inflammatory arthritis; nasal chondritis; ocular inflammation; laryngeal or tracheal chondritis; cochlear and/or vestibular dysfxn</p>
<p class="bl"><span class="sbl">•</span> 40% of cases a/w immunologic disorder (eg, RA, SLE, vasc., Sjögren’s), cancer or MDS</p>
<p class="bl"><span class="sbl">•</span> Clinical diagnosis based on exam with multiple sites of cartilaginous inflammation</p>
<p class="bl"><span class="sbl">•</span> Labs: ↑ ESR &amp; CRP, leukocytosis, eosinophilia, anemia of chronic inflammation</p>
<p class="bl"><span class="sbl">•</span> Bx (not req for dx): proteoglycan depletion, perichondrial inflammation and replacement with granulation tissue and fibrosis; immunofluorescence with Ig and C3 deposits</p>
<p class="bl"><span class="sbl">•</span> Screen for pulm (PFTs, CXR/CT, ± bronch) and cardiac (ECG, TTE) involvement</p>
<p class="bl"><span class="sbl">•</span> Therapy guided by disease activity and severity: <b class="calibre4">steroids</b> 1<sup class="calibre15">st</sup> line; NSAIDs, dapsone for sx control of arthralgias and mild disease; MTX, AZA, or biologics for steroid-sparing; cyclophosphamide for organ-threatening disease</p>
<h2 class="ct"><a id="h102" class="calibre7"></a><a id="page_8-5" class="calibre7"></a><a href="part0002.html#rh113" class="calibre7">CRYSTAL DEPOSITION ARTHRITIDES</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre17"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Comparison of Gout and Pseudogout</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tabh"><b class="calibre4">Gout</b> <span class="tfont1">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">11</span><span class="tfont1">;364:443)</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Pseudogout</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Rheum</i></span> <span class="tfont1">2009;48:7</span><span class="tfont1">11</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Acute clinical</b></p></td>
<td class="bg0-br"><p class="tabh"><i class="calibre3">S</i>udden onset painful <i class="calibre3">mono- articular</i> arthritis (classically <b class="calibre4">podagra</b> [MTP of great toe]) or bursitis; frequently nocturnal</p>
<p class="tab">May be <i class="calibre3">polyarticular</i> in subseq flares</p>
<p class="tab">Can mimic cellulitis (esp in foot)</p></td>
<td class="bg0-b"><p class="tab">Mono- or asymmetric oligoarthritis (esp knees, wrists and MCP joints); rare axial involvement (eg, crowned dens syndrome)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Chronic clinical</b></p></td>
<td class="bg0-br"><p class="tab">Solid crystal deposition (<b class="calibre4">tophus</b>) in joints (esp. toes, fingers, wrists, knees) &amp; tissue (esp. olecranon bursa, pinna, Achilles)</p></td>
<td class="bg0-b"><p class="tab">“Pseudo-RA” w/ polyarticular arthritis w/ morning stiffness or “Pseudo-OA”</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Assoc. conditions</b></p></td>
<td class="bg0-br"><p class="tab">Metabolic syndrome; CKD; CHF</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">3 H’s</b>: <span class="underline">H</span>yperparathyroidism, <span class="underline">H</span>ypo-magnesemia, <span class="underline">H</span>emochromatosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Crystal</b></p></td>
<td class="bg0-br"><p class="tab">Monosodium urate (MSU)</p></td>
<td class="bg0-b"><p class="tab">Calcium pyrophosphate dihydrate</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Polarized microscopy</b><a id="st14" class="calibre1"></a><a href="part0013.html#sst14" class="calibre1">*</a></p></td>
<td class="bg0-br"><p class="tab">Needle-shaped, <b class="calibre4">negatively birefringent</b> (yellow)</p></td>
<td class="bg0-b"><p class="tab">Rhomboid-shaped, weakly <b class="calibre4">positively birefringent</b> (blue)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Radio- graphic findings</b></p></td>
<td class="bg0-br"><p class="tab">Early = nonspecific tissue swelling</p>
<p class="tabh">Late = tophus, joint erosions w/ overhanging edges</p>
<p class="tab">“Double contour sign” on MSK US</p>
<p class="tab">DECT: UrA vs Ca deposits</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Chondrocalcinosis:</b> linear densities within articular cartilage; often found in menisci, fibrocartilage of wrist, hands, symphysis pubis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Other</b></p></td>
<td class="bg0-r"><p class="tab">a/w uric acid stones; urate nephropathy</p></td>
<td class="bg"><p class="tab">✔ Ca, Mg, Fe, ferritin, TIBC, UrA, PTH in young or severe cases</p></td>
</tr>
</table>
<p class="tsr"><i class="calibre3"><a id="sst14" class="calibre1"></a><a href="part0013.html#st14" class="calibre1">*</a>Crystals should be intracellular; infection can coexist with acute attacks</i>, ∴ <i class="calibre3">always</i> ✔ <i class="calibre3">Gram stain &amp; Cx</i></p>
<p class="h">G<small class="calibre30">OUT</small></p>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">Lancet</i> 2016;388:2039)</span></p>
<p class="bl"><span class="sbl">•</span> Humans lack enzyme to metabolize urate (end-product of purine metabolism)</p>
<p class="bl"><span class="sbl">•</span> MSU crystal deposition promotes inflammation in joints and peri-articular tissue;</p>
<p class="bl"><span class="sbl">•</span> ♂ &gt; ♀ (9:1); peak incidence 5<sup class="calibre15">th</sup> decade; most common cause of inflammatory arthritis in ♂ over 30 y; <i class="calibre3">rare</i> in premenopausal ♀ (estrogens promote renal urate excretion)</p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2012;71:1448)</span></p>
<p class="bl"><span class="sbl">•</span> UrA underexcretion (85–90%): meds (eg, diuretics); idiopathic; ↓ renal function; obesity</p>
<p class="bl"><span class="sbl">•</span> Uric acid (UrA) overproduction (10–15%): ↑ meat, seafood, EtOH, psoriasis, idiopathic, myelo- and lymphoproliferative disease, chronic hemolytic anemia, cytotoxic drugs, rare inherited enzyme defic, genetic variants <span class="s1r">(<i class="calibre3">Lancet</i> 2008;372:1953)</span></p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">UrA is not diagnostic:</b> 25% of measurements nl during flare; ± ↑ WBC &amp; ESR</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arthrocentesis is gold standard:</b> negatively birefringent needle-shaped MSU crystals</p>
<p class="bl"><span class="sbl">•</span> 2015 ACR/EULAR Classification Criteria <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2015;74:1789)</span> used 1° in research</p>
<p class="h2a">Acute treatment <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2017;76:29)</span></p>
<p class="bl"><span class="sbl">•</span> No superior option; start w/in 24 h of sx onset; continue until acute flare resolves; for severe cases, consider combination therapy; rest and ice; w/o treatment self-limited in 3–10 d</p>
<p class="bl"><span class="sbl">•</span> Continue urate-lowering therapy during attack if already taking</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre16"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Acute Treatment for Gout</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabheadc">Drug</p></td>
<td class="bg0-br"><p class="tabheadc">Initial Dose</p></td>
<td class="bg0-b"><p class="tabhead">Comments</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">NSAIDs</b> (nonselect or COX-2)</p></td>
<td class="bg0-br"><p class="tabc">Full anti-inflammatory dose → tapering</p></td>
<td class="bg0-b"><p class="tab">Gastritis &amp; GIB; avoid in CKD &amp; CVD</p>
<p class="tab">≈ efficacy among NSAIDs</p>
<p class="tab">never compared with colchicine</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Colchicine</b> (PO; IV no longer available in U.S.)</p></td>
<td class="bg0-br"><p class="tabc">1.2 mg then 0.6 mg 1 h later → 0.6 mg bid</p></td>
<td class="bg0-b"><p class="tabh">N/V, diarrhea (↑ w/ ↑ dose); ↓ dose in renal insufficiency (however, not nephrotoxic)</p>
<p class="tab">a/w BM supp., myopathy, neuropathy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Corticosteroids</b> (PO, IA, IV, IM) <i class="calibre3">or</i> <b class="calibre4">Corticotropin</b></p></td>
<td class="bg0-br"><p class="tabc">eg, prednisone ~0.5 mg/kg/d × 5–10 d ± taper</p></td>
<td class="bg0-b"><p class="tab">Rule out joint infection 1<sup class="calibre35">st</sup></p>
<p class="tab">Comparable to NSAID as 1<sup class="calibre35">st</sup>-line treatment Corticosteroid injection if &lt;3 joints</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc"><b class="calibre4">IL-1 inhibitors</b></p>
<p class="tabc"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Curr Opin Rheumatol</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;27:</span><span class="tfont1">1</span><span class="tfont1">56)</span></p></td>
<td class="bg0-r"><p class="tabc">anakinra (100 mg SC qd × 3 d)</p>
<p class="tabc">canakinumab (150 mg SC × 1)</p></td>
<td class="bg"><p class="tabh">↑↑ cost; anakinra a/w injection site pain <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Arthritis Res Ther</i></span> <span class="tfont1">2007;9:R28)</span></p>
<p class="tabh">Canakinumab approved in EU <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Ann Rheum Dis</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">2;7</span><span class="tfont1">1</span><span class="tfont1">:</span><span class="tfont1">1</span><span class="tfont1">839;</span> <span class="tfont1"><i class="calibre3">Arth Rheum</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">0;62:3064)</span></p></td>
</tr>
</table>
<p class="h2a"><a id="page_8-6" class="calibre1"></a>Chronic treatment <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2017;76:29)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Approach:</b> if ≥2 attacks/y, polyarticular attack, tophus, joint erosions, GFR &lt;60, or urolithiasis → start urate-lowering therapy + pharmacologic ppx to ↓ risk of acute attacks</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urate-lowering therapy (ULT):</b> goal UrA &lt;6 mg/dL or &lt; 5 mg/dl if tophi; when starting ULT, always give with pharm ppx as below; <i class="calibre3">do NOT d/c during acute attack or due to AKI</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pharmacologic prophylaxis:</b> continue 6 mo w/ above Rx or longer if frequent attacks:</p>
<p class="bl1">low-dose <b class="calibre4">colchicine</b> (~50% ↓ risk of acute flare; <i class="calibre3">J Rheum</i> 2004;31:2429), <b class="calibre4">NSAIDs</b> (less evidence; <i class="calibre3">Ann Rheum Dis</i> 2006;65:1312), low-dose <b class="calibre4">steroids</b>, <b class="calibre4">IL-1 inhibitors</b> (see above)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lifestyle</b> Δs <span class="s1r">(<i class="calibre3">Rheum Dis Clin NA</i> 2014;40:581)</span>: ↓ intake of meat, EtOH &amp; seafood, ↑ low-fat dairy products, wt loss, avoid dehydration</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre33"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Urate-Lowering Therapy (Chronic Treatment for Gout)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Drug (route)</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Mechanism</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Allopurinol</b> (PO)</p></td>
<td class="bg0-br"><p class="tabc">Xanthine oxidase</p>
<p class="tabc">inhibitor</p></td>
<td class="bg0-b"><p class="tab">1<sup class="calibre35">st</sup> line; adjust starting dose in CKD; titrate ↑ q2–5wk;</p>
<p class="tabh">a/w rash, hypersensitivity syndrome (see below), BM suppression (<b class="calibre4">avoid w/ AZA/6-MP</b>), diarrhea, N/V, hepatitis; monitor CBC, LFT’s; <i class="calibre3">not nephrotoxic</i></p>
<p class="tab">max dose = 800 mg/d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Febuxostat</b> (PO)</p></td>
<td class="bg0-br"><p class="tabc">Nonpurine xanthine oxidase inhib</p></td>
<td class="bg0-b"><p class="tab">2<sup class="calibre35">nd</sup> line; use if allopurinol intolerant;</p>
<p class="tab">a/w LFT, rash, arthralgias, N/V;</p>
<p class="tab"><b class="calibre4">avoid w/ AZA/6-MP</b> (BM suppress);</p>
<p class="tab">start 40 mg, max dose = 120 mg/d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pegloticase</b> (IV)</p></td>
<td class="bg0-br"><p class="tabc">Recombinant uricase</p></td>
<td class="bg0-b"><p class="tab">For refractory tophaceous gout; infusion reactions (including anaphylaxis); Ab formation may limit use <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JAMA</i></span> <span class="tfont1">20</span><span class="tfont1">11</span><span class="tfont1">;306:7</span><span class="tfont1">11</span><span class="tfont1">)</span>; <b class="calibre4">avoid w/ G6PD deficiency</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Probenecid</b> (PO)</p></td>
<td class="bg0-r"><p class="tabc">Uricosuric</p></td>
<td class="bg"><p class="tab">Rarely used; risk of urolithiasis</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Allopurinol hypersensitivity syndrome:</b> 10–25% mortality; ↓ risk by <i class="calibre3">starting</i> w/ dose 100 mg/d if eGFR &gt;40 or 50 mg/d if eGFR ≤40; titrate up by 100 mg/d (if eGFR &gt;40) or 50 mg/d (if eGFR ≤40) q2–5wk until UrA &lt;6 mg/dL (dose can be &gt;300 mg/d even in CKD). <i class="calibre3">Associated with HLA-B5801</i>, esp. Han Chinese, Koreans, Thai; screen in these high-risk populations prior to initiating allopurinol <span class="s">(<i class="calibre3">Curr Opin Rheumatol</i> 2014;26:16)</span>.</p>
<p class="h">C<small class="calibre30">ALCIUM</small> P<small class="calibre30">YROPHOSPHATE</small> D<small class="calibre30">IHYDRATE</small> (CPPD) D<small class="calibre30">EPOSITION</small> D<small class="calibre30">ISEASE</small>/P<small class="calibre30">SEUDOGOUT</small></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Deposition of CPPD crystals w/in tendons, ligaments, articular capsules, synovium, cartilage; frequently asymptomatic</p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">Rheumatology</i> 2012;51:2070)</span></p>
<p class="bl"><span class="sbl">•</span> Most cases <b class="calibre4"><i class="calibre3">idiopathic</i>;</b> consider further metabolic eval in young (&lt;50 y) and florid forms</p>
<p class="bl"><span class="sbl">•</span> Metabolic (<i class="calibre3">3 H’s</i>): hemochromatosis; hyperparathyroidism; hypomagnesemia (esp. in Gitelman’s or Bartter’s syndromes)</p>
<p class="bl"><span class="sbl">•</span> Joint trauma (incl. previous surgery); intra-articular hyaluronate can precipitate attacks</p>
<p class="bl"><span class="sbl">•</span> Familial chondrocalcinosis (autosomal dominant disorder); early-onset, polyarticular dis.</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Rheum Dis Clin NA</i> 2014;40:207)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chondrocalcinosis:</b> calcification of cartilage, resulting from CPPD deposition in articular cartilage, fibrocartilage or menisci</p>
<p class="bl1">↑ incidence w/ age; 20% &gt;60 y have knee chondrocalcinosis in autopsy studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pseudogout:</b> acute CPPD crystal-induced mono- or asymmetric oligoarticular arthritis, <i class="calibre3">indistinguishable from gout except through synovial fluid exam for crystals</i></p>
<p class="bl1">location: <b class="calibre4">knees</b>, <b class="calibre4">wrists</b> and MCP joints</p>
<p class="bl1">precipitants: surgery, trauma, or severe illness</p>
<p class="bl"><span class="sbl">•</span> Chronic forms: “pseudo-RA” and pyrophosphate arthropathy (may involve axial skeleton, resembles OA)</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Arthrocentesis is gold standard: <b class="calibre4">rhomboid shaped, weakly <i class="calibre3">positively</i> birefringent crystals</b> (yellow <i class="calibre3">perpendicular</i> &amp; blue <i class="calibre3">parallel</i> to axis on polarizer; see table above)</p>
<p class="bl"><span class="sbl">•</span> Radiographs: see table above</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2016;374:2575)</span></p>
<p class="bl"><span class="sbl">•</span> Asymptomatic chondrocalcinosis requires no treatment</p>
<p class="bl"><span class="sbl">•</span> Acute therapy for pseudogout: no RCTs, extrapolated from practice in gout; ∴ same as for gout, though colchicine not as effective</p>
<p class="bl"><span class="sbl">•</span> If associated metabolic disease, Rx of underlying disorder <i class="calibre3">may</i> improve arthritis sx</p>
<p class="bl"><span class="sbl">•</span> Low-dose daily colchicine or NSAID may be effective for prophylaxis or chronic arthropathy</p>
<h2 class="ct"><a id="h103" class="calibre7"></a><a id="page_8-7" class="calibre7"></a><a href="part0002.html#rh114" class="calibre7">SERONEGATIVE SPONDYLOARTHRITIS</a></h2>
<p class="h2a">Definition and classification system <span class="s">(<i class="calibre3">NEJM</i> 2016;374:2563)</span></p>
<p class="bl"><span class="sbl">•</span> Spondyloarthritis (SpA): group of inflammatory disorders that share common clinical manifestations: inflammatory spine disease, peripheral arthritis, enthesitis (see below), and extra-articular manifestations (primarily ocular and skin disease)</p>
<p class="bl"><span class="sbl">•</span> Seronegative = absence of autoantibodies</p>
<p class="bl"><span class="sbl">•</span> Subtypes: ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), IBD-associated arthritis, juvenille SpA and undifferentiated</p>
<p class="h2a">Epidemiology &amp; pathogenesis <span class="s">(<i class="calibre3">Nat Rev Rheumatol</i> 2015;11:110)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence 0.5–2% worldwide; AS and non-radiographic axial SpA most common</p>
<p class="bl"><span class="sbl">•</span> HLA-B27 accounts for ~30% of attributable genetic risk but not required for diagnosis</p>
<p class="bl"><span class="sbl">•</span> Environmental factors likely critical for disease, esp reactive arthritis (ie, infection)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre70"/>
<col class="calibre71"/>
<col class="calibre71"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Spondyloarthritis (SpA) Epidemiology and Key Presentation Features</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Disease</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Epidemiology</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Key Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AS</p></td>
<td class="bg0-br"><p class="tab">♂:♀ = 3:1; onset in teens to mid- 20s (rare after 40 y)</p></td>
<td class="bg0-b"><p class="tab">Progressive limitation of spinal motion, “bamboo spine,” ⊕ Schober test</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Psoriatic arthritis</p></td>
<td class="bg0-br"><p class="tab">♂ = ♀; peak incidence 45–54 y; seen in 20–30% of Pts w/ psoriasis</p></td>
<td class="bg0-b"><p class="tab">In 13–17% arthritis precedes skin findings by yrs; does not correlate with psoriasis activity; a/w HIV</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Reactive arthritis</p></td>
<td class="bg0-br"><p class="tab">♂ &gt;&gt; ♀; 20–40 y; 10–30 d after</p>
<p class="tab"><b class="calibre4">GI or GU infxn</b><a id="st15" class="calibre1"></a><a href="part0013.html#sst15" class="calibre1">*</a> in genetically susceptible host</p></td>
<td class="bg0-b"><p class="tab">Previously “Reiter’s syndrome”: arthritis, urethritis, and conjunctivitis.</p>
<p class="tab">Most resolve w/in 12 mo.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">IBD- associated</p>
<p class="tab">arthritis</p></td>
<td class="bg0-r"><p class="tab">♂ = ♀; seen in 20% of IBD Pts; Crohn’s &gt; UC</p></td>
<td class="bg"><p class="tab">Type I &lt;5 joints: correlates w/ IBD activ.</p>
<p class="tabh">Type II &gt;5 joints or axial disease: does not correlate w/ IBD activity</p></td>
</tr>
</table>
<p class="tsr"><a id="sst15" class="calibre1"></a><a href="part0013.html#st15" class="calibre1">*</a>GU: Chlamydia, Ureaplasma urealyticum; GI: Shigella, Salmonella, Yersinia, Campylobacter, C. diff.</p>
<p class="h2a">Major clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2017;390:73)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inflammatory back pain:</b> SI joints (<b class="calibre4">sacroiliitis</b>), apophyseal joints of spine</p>
<p class="bl1">characterized by <b class="calibre4">IPAIN</b> (<span class="underline">I</span>nsidious onset, <span class="underline">P</span>ain at night, <span class="underline">A</span>ge of onset &lt;40 y, <span class="underline">I</span>mproves w/ exercise/hot water, <span class="underline">N</span>o improvement w/ rest), a.m. stiffness, <i class="calibre3">responsive to NSAIDs</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral arthritis:</b> typically asymmetric, oligoarticular, large joints, lower &gt; upper limbs; however, can be symmetric &amp; polyarticular (thus, mimic RA), espec. in psoriatic arthritis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Enthesitis:</b> inflammation at site of tendon/ligament insertion into bone, esp Achilles, plantar fascia (calcaneal insertion), pre-patellar, elbow epicondyles</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rigidity of spine:</b> bamboo spine by X-ray, ankylosis due to progressive growth of bony spurs that bridge intervertebral disc</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dactylitis:</b> “sausage digit,” inflammation of entire digit (joint + tenosynovial inflamm)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uveitis:</b> anterior uveitis <i class="calibre3">most common extra-articular manifestation</i> in seronegative SpA<i class="calibre3">;</i> usually unilateral and p/w pain, red eye, blurry vision, photophobia</p>
<p class="bl"><span class="sbl">•</span> Subtypes also distinguished by <i class="calibre3">axial</i> vs <i class="calibre3">peripheral</i> predominant involvement</p>
<p class="image1"><img src="../images/00125.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_8-8" class="calibre1"></a>Clinical assessment <span class="s">(<i class="calibre3">Nat Rev Rheumatol</i> 2012;8:253)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Seronegative:</b> notable for <i class="calibre3">absence</i> of rheumatoid factor or autoantibodies; ± ↑ESR/CRP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HLA-B27:</b> nonspecific, b/c common in general population (6–8%); most useful when high clinical suspicion but nl imaging; ⊕ 90% of Pts w/ AS, but only 20–80% in other SpA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Axial disease physical exam</b></p>
<p class="bl1">The following are not specific PEx findings but useful in monitoring disease during Rx:</p>
<p class="bl1">Lumbar flexion deformity assessed by <b class="calibre4">modified Schober’s test</b> (⊕ if &lt;5 cm ↑ in distance between a point 5 cm below the lumbosacral jxn and another point 10 cm above, when going from standing to maximum forward flexion)</p>
<p class="bl1">T-spine mobility (extension) and kyphosis severity measured by <b class="calibre4">occiput-to-wall distance</b> (although occiput-to-wall distance also increased in osteoporotic kyphosis)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infectious evaluation for reactive arthritis</b> (⊖ studies do not r/o)</p>
<p class="bl1"><b class="calibre4">GU:</b> U/A, PCR of urine and/or genital swab for <i class="calibre3">Chlamydia;</i> urethritis usually due to <i class="calibre3">Chlamydia</i> infxn preceding arthritis, but can also see sterile urethritis post dysentery</p>
<p class="bl1"><b class="calibre4">GI:</b> ✔ stool Cx, <i class="calibre3">C. diff</i> toxin. Consider HIV in workup for reactive or psoriatic arthritis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Radiology</b></p>
<p class="bl1">MRI preferred for <i class="calibre3">early</i> detection of inflammation (sacroiliitis)</p>
<p class="bl1">Plain films detect late structural changes (SI erosions/sclerosis)</p>
<p class="bl2">Calcification of spinal ligaments w/ bridging symm syndesmophytes (“bamboo spine”)</p>
<p class="bl2">Squaring and generalized demineralization of vertebral bodies (“shiny corners”)</p>
<p class="bl">Descriptions of skin manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Psoriasis:</b> erythematous plaques with sharply defined margins often w/ thick silvery scale</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Circinate balanitis:</b> shallow, painless ulcers of glans penis and urethral meatus</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Keratoderma blennorrhagica:</b> hyperkeratotic lesions on soles of feet, scrotum, palms, trunk, scalp</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Erythema nodosum:</b> red tender nodules in subcutan. fat (panniculitis), typically on shins Ddx includes idiopathic, infxn, sarcoid, drug rxn, vasculitis, IBD, lymphoma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pyoderma gangrenosum:</b> neutrophilic dermatosis → painful ulcers w/ violaceous border Ddx incl. idiopathic, IBD, RA, heme and solid malignancies, MGUS, MDS, polycyth. vera</p>
<p class="h2a">Psoriatic arthritis subtypes <span class="s">(<i class="calibre3">NEJM</i> 2017;376:957; 2018;391:2273 &amp; 2285)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Monoarticular/oligoarticular</b> (eg, large joint, DIP joint, dactylitic digit): most common initial manifestation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polyarthritis</b> (small joints of the hands/feet, wrists, ankles, knees, elbows): indistinguishable from RA, but often asymmetric</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arthritis mutilans:</b> severe destructive arthritis with bone resorption, esp. hands</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Axial disease:</b> unilateral/asymmetric sacroiliitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">DIP-limited:</b> good correlation with nail pitting and onycholysis</p>
<p class="h2a">Treatment approach <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2012;71:319; <i class="calibre3">Arth Rheum</i> 2016;68:282)</span></p>
<p class="bl"><span class="sbl">•</span> Untreated disease may lead to irreversible structural damage and associated ↓ function</p>
<p class="bl"><span class="sbl">•</span> Early physiotherapy beneficial</p>
<p class="bl"><span class="sbl">•</span> Tight control of inflammation improves joint outcomes in PsA <span class="s1r">(<i class="calibre3">Lancet</i> 2015;386:2489)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">NSAIDs:</b> 1<sup class="calibre15">st</sup> line; rapidly ↓ stiffness and pain; prolonged, continuous administration may modify disease course but associated w/ GI and CV toxicity <span class="s1r">(<i class="calibre3">Cochrane Database Syst Rev</i> 2015;17:CD010952)</span>; may exacerbate IBD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intra-articular corticosteroids</b> in mono- or oligoarthritis; limited role for systemic steroids, esp. for axial disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Conventional DMARDs</b> (eg, MTX, SAS, leflunomide): no efficacy for axial disease or enthesitis; may have role in peripheral arthritis, uveitis, and extra-articular manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anti-TNFs:</b> effective for both axial and peripheral manifestations, improves function and may slow progression of structural changes <span class="s1r">(<i class="calibre3">Curr Rheumatol Rep</i> 2012;14:422)</span>; adalimumab or infliximab preferred if inflammatory eye disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anti-IL17A</b> (secukinumab, ixekizumab): for both axial and peripheral PsA &amp; for ankylosing spondylitis <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:1329 &amp; 2534; <i class="calibre3">Lancet</i> 2015;386:1137)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anti-IL12/23</b> (ustekinumab): for both axial and peripheral PsA <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2014;73:990)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PDE-4 inhibitor</b> (apremilast): peripheral arthritis in PsA <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2014;73:1020)</span>; associated with GI side effects and significant wt loss</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">JAK inhibitor:</b> for anti-TNF resistant peripheral PsA <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1525)</span></p>
<p class="bl"><span class="sbl">•</span> Psoriasis (skin) also responds to anti-TNF, anti-IL17A, anti-IL12/23, PDE-4 inhib, JAK inhib</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Other:</b></p>
<p class="bl1">Abx in reactive arthritis if evidence of active infxn; consider prolonged abx for refractory <i class="calibre3">Chlamydia</i> ReA <span class="s1r">(<i class="calibre3">Arthritis Rheum</i> 2010;62:1298)</span></p>
<p class="bl1">Involve ophthalmologist for any evidence of inflammatory eye disease (may benefit from steroid eye drops or intravitreal steroid injections)</p>
<p class="bl1">Treat underlying IBD when appropriate</p>
<h2 class="ct"><a id="h104" class="calibre7"></a><a id="page_8-9" class="calibre7"></a><a href="part0002.html#rh115" class="calibre7">INFECTIOUS ARTHRITIS &amp; BURSITIS</a></h2>
<p class="h">E<small class="calibre30">TIOLOGIES</small> &amp; D<small class="calibre30">IAGNOSIS</small> <small class="calibre30">OF</small> I<small class="calibre30">NFECTIOUS</small> A<small class="calibre30">RTHRITIS</small></p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">Curr Rheumatol Rep</i> 2013;15:332)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bacterial</b> (nongonococcal): early diagnosis and treatment essential</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Gonococcal</b> (<i class="calibre3">N. gonorrhea</i>): consider in sexually active young adults</p>
<p class="bl"><span class="sbl">•</span> Viral: parvovirus, HCV, HBV, acute HIV, Chikungunya; mainly polyarticular, may mimic RA</p>
<p class="bl"><span class="sbl">•</span> Mycobacterial: monoarticular or axial (Pott’s disease)</p>
<p class="bl"><span class="sbl">•</span> Fungal: <i class="calibre3">Candida</i> (esp. prosthetic joints), coccidiomycosis (valley fever), histoplasmosis</p>
<p class="bl"><span class="sbl">•</span> Other: Lyme, <i class="calibre3">Mycoplasma</i>, <i class="calibre3">Salmonella</i> (2° to anti-TNF Rx), Brucellosis, <i class="calibre3">T. whipplei</i></p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">JAMA</i> 2007;297:1478)</span></p>
<p class="bl"><span class="sbl">•</span> H&amp;P w/ poor sensitivity and specificity for septic arthritis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arthrocentesis in acute onset inflammatory monoarthritis</b> to r/o septic arthritis; if possible obtain fluid sample prior to starting antibiotics</p>
<p class="bl"><span class="sbl">•</span> Do not tap through overlying infected area to prevent introducing infxn into joint space</p>
<p class="bl"><span class="sbl">•</span> ✔ Fluid cell count w/ diff, Gram stain, bacterial culture, crystal analysis; <b class="calibre4">WBC</b> &gt;<b class="calibre4">50k</b></p>
<p class="bl1"><b class="calibre4">w/ PMN predominance</b> suspicious for bact. infxn; <i class="calibre3">crystals do not r/o septic arthritis!</i></p>
<p class="h">B<small class="calibre30">ACTERIAL</small> (N<small class="calibre30">ONGONOCOCCAL</small>) A<small class="calibre30">RTHRITIS</small></p>
<p class="h2a">Epidemiology &amp; risk factors</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Immunocompromised host:</b> DM, EtOH use, HIV, age &gt;80, SLE, cancer, steroid use, etc.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Damaged joints:</b> RA, OA, gout, trauma, prior surgery/prosthetic, prior arthrocentesis (rare)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bacterial seeding:</b> bacteremia especially secondary to IVDU or endocarditis; direct inoculation or spread from contiguous focus (eg, cellulitis, septic bursitis, osteo)</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">JAMA</i> 2007;297:1478; <i class="calibre3">Lancet</i> 2010;375:846)</span></p>
<p class="bl"><span class="sbl">•</span> Acute onset <b class="calibre4">monoarticular arthritis</b> (&gt;80%) w/ pain (Se 85%), swelling (Se 78%), warmth</p>
<p class="bl"><span class="sbl">•</span> Location: <b class="calibre4">knee</b> (most common), hip, wrist, shoulder, ankle. In IVDU, tends to involve other areas including axial joints (eg, SI, symphysis pubis, sternoclavicular, manubrial joints).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Constit. sx:</b> fevers (Se 57%), rigors (Se 19%), sweats (Se 27%), malaise, myalgias, pain</p>
<p class="bl"><span class="sbl">•</span> Infection can track from initial site to form fistulae, abscesses, or osteomyelitis</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Septic bursitis must be differentiated from septic intra-articular effusion</i></p>
<p class="h2a">Additional diagnostic studies <span class="s">(<i class="calibre3">JAMA</i> 2007;297:1478)</span></p>
<p class="bl"><span class="sbl">•</span> Synovial fluid: <b class="calibre4">WBC usually</b> &gt;<b class="calibre4">50k</b> (Se 62%, Sp 92%) but can be &lt;10k, &gt;<b class="calibre4">90% polys;</b> Gram stain ⊕ in ~75% of <i class="calibre3">Staph</i>, ~50% of GNR; Cx ⊕ in &gt;90%; synovial bx most sens.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Leukocytosis</b> (Se 90%, Sp 36%); <b class="calibre4">elevated ESR/CRP</b> (Se &gt;90%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Blood cultures</b> ⊕ in &gt;50% of cases, ~80% when more than 1 joint involved</p>
<p class="bl"><span class="sbl">•</span> X-rays of joints should be obtained but usually normal until after ~2 wk of infection when may see bony erosions, joint space narrowing, osteomyelitis, and periostitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT &amp; MRI</b> useful esp. for suspected hip infection or epidural abscess</p>
<p class="h2a">Treatment for native joints <span class="s">(<i class="calibre3">Curr Rheumatol Rep</i> 2013;15:332)</span></p>
<p class="bl"><span class="sbl">•</span> Prompt empiric antibiotics guided by Gram stain after surgical drainage. If Gram stain ⊖, empiric Rx w/ vancomycin; add anti-pseudomonal agent if elderly, immunocompromised.</p>
<p class="imagef"><img src="../images/00126.jpeg" alt="" class="calibre2"/></p>
<p class="fn">* Can later Δ to antistaphylococcal penicillin or cefazolin based on sensitivities</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IV antibiotics</b> × ≥2 wk followed by oral antibiotics; varies by clinical course &amp; microbiology</p>
<p class="bl"><span class="sbl">•</span> Joint must be <b class="calibre4">drained</b>, often serially; arthroscopic drainage for larger joints and as initial treatment but may also be accomplished by arthrocentesis. Serial synovial fluid analyses should demonstrate ↓ in WBC and sterility.</p>
<p class="bl"><span class="sbl">•</span> 10–15% mortality (up to 50% w/ polyarticular); depends on virulence, time to Rx, host</p>
<p class="h2a"><a id="page_8-10" class="calibre1"></a>Prosthetic joint infections <span class="s">(<i class="calibre3">Infect Dis Clin North Am</i> 2012;26:29; <i class="calibre3">CID</i> 2013;56:e1)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ risk in first 2 y s/p procedure; rate generally low (0.5–2.4%); risk factors include obesity, RA, immunocompromised state, steroids, &amp; superficial surgical site infxn</p>
<p class="bl"><span class="sbl">•</span> Staphylococci (coag negative &amp; <i class="calibre3">S. aureus</i>) in &gt;50%; polymicrobial in 10–20%</p>
<p class="bl"><span class="sbl">•</span> Early (&lt;3 mo s/p surgery) or delayed (3–24 mo) onset typically acquired during implantation; early w/ virulent organisms (eg, MRSA) and delayed w/ less virulent organisms (eg, <i class="calibre3">P. acnes</i>, coag negative <i class="calibre3">Staph</i>) &amp; more indolent presentation</p>
<p class="bl"><span class="sbl">•</span> Late (&gt;24 mo) onset typically related to secondary hematogenous seeding</p>
<p class="bl"><span class="sbl">•</span> Diagnosis requires arthrocentesis by orthopedics; ESR &amp; CRP (CRP Se 73–91%, Sp 81– 86%; <i class="calibre3">NEJM</i> 2009;361:787) can be helpful</p>
<p class="bl"><span class="sbl">•</span> Treatment typically requires prolonged abx &amp; 2-stage joint replacement (joint retention a/w ~40% failure rate; <i class="calibre3">CID</i> 2013;56:182) or life-long suppressive abx. <i class="calibre3">ID and orthopedics consultation required.</i></p>
<p class="h">D<small class="calibre30">ISSEMINATED</small> G<small class="calibre30">ONOCOCCAL</small> I<small class="calibre30">NFECTION</small> (DGI)</p>
<p class="h2a">Epidemiology <span class="s">(<i class="calibre3">Infect Dis Clin North Am</i> 2005;19:853)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">N. gonorrhea;</i> most frequent type of infectious arthritis in sexually active young adults</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Normal host</b> as well as Pts w/ deficiencies of terminal components of complement</p>
<p class="bl"><span class="sbl">•</span> ♀:♂ = 4:1; ↑ incidence during menses, pregnancy, &amp; postpartum period, SLE; ↑ incidence in homosexual males; rare after age 40 y</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Preceded by <b class="calibre4">mucosal infection</b> (eg, cervix, urethra, anus, or pharynx) that is often asx</p>
<p class="bl"><span class="sbl">•</span> Two distinct syndromes, although Pts can have both:</p>
<p class="bl1"><b class="calibre4">Joint localized:</b> purulent arthritis (40%), usually 1–2 joints (knees &gt; wrists &gt; ankles)</p>
<p class="bl1"><b class="calibre4">DGI:</b> triad of polyarthralgias, tenosynovitis, skin lesions</p>
<p class="bl1">1) <i class="calibre3">polyarthralgias</i>: migratory joint pain, can affect small or large joints</p>
<p class="bl1">2) <i class="calibre3">tenosynovitis</i>: pain/inflammation of tendon and its sheath in wrists, fingers, ankles, toes</p>
<p class="bl1">3) <i class="calibre3">skin lesions</i>: gunmetal gray pustules with erythematous base on extremities &amp; trunk</p>
<p class="bl"><span class="sbl">•</span> Rare complications: Fitz-Hugh-Curtis syndrome (perihepatitis), pericarditis, meningitis, myocarditis, osteomyelitis from direct extension of joint-localized infection</p>
<p class="h2a">Additional diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Synovial fluid: <b class="calibre4">WBC</b> &gt;<b class="calibre4">50k</b> (but can be &lt;10k), <b class="calibre4">poly predominant</b></p>
<p class="bl1">Gram stain ⊕ in ~25%; culture ⊕ in up to 50% if done w/ Thayer-Martin media</p>
<p class="bl"><span class="sbl">•</span> Blood culture: more likely ⊕ in DGI; rarely in joint localized disease</p>
<p class="bl"><span class="sbl">•</span> Gram stain and culture of skin lesions occasionally ⊕</p>
<p class="bl"><span class="sbl">•</span> Cervical, urethral, pharyngeal, rectal PCR or cx on Thayer-Martin media; ✔ <i class="calibre3">Chlamydia</i></p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ceftriaxone × 7–14 d w/ empiric azithromycin 1g x 1 dose</b> for <i class="calibre3">Chlamydia</i> (fluoroquinolones no longer recommended due to resistance)</p>
<p class="bl"><span class="sbl">•</span> Joint arthroscopy/lavage may be required for purulent arthritis; rarely &gt;1 time</p>
<p class="h">O<small class="calibre30">LECRANON</small> &amp; P<small class="calibre30">REPATELLAR</small> B<small class="calibre30">URSITIS</small></p>
<p class="h2a">Epidemiology &amp; risk factors <span class="s">(<i class="calibre3">Infect Dis North Am</i> 2005;19:991)</span></p>
<p class="bl"><span class="sbl">•</span> &gt;150 bursae in the body; 2 most commonly infected are <b class="calibre4">olecranon</b> and <b class="calibre4">prepatellar</b></p>
<p class="bl"><span class="sbl">•</span> Most commonly (esp. superficial bursae) due to direct trauma, percutaneous inoculation, or contiguous spread from adjacent infection (eg, cellulitis)</p>
<p class="bl"><span class="sbl">•</span> Other risk factors: recurrent noninfectious inflammation (eg, gout, RA, CPPD), diabetes</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">S. aureus</i> (80%) most common, followed by streptococci</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Physical exam: discrete bursal swelling, erythema, maximal tenderness at center of bursa with preserved joint range of motion</p>
<p class="bl"><span class="sbl">•</span> Aspirate bursa if concern for infxn, ✔ cell count, Gram stain, bacterial cx, crystals</p>
<p class="bl1"><b class="calibre4">WBC</b> &gt;<b class="calibre4">20k w/ poly predominance</b> suspicious for bacterial infection, but lower counts common (crystals do <i class="calibre3">not</i> rule out septic bursitis!)</p>
<p class="bl"><span class="sbl">•</span> Assess for adjacent joint effusion, which can also be septic</p>
<p class="bl"><span class="sbl">•</span> Do not tap through infected skin to avoid introducing infxn into bursa</p>
<p class="h2a">Initial therapy</p>
<p class="bl"><span class="sbl">•</span> Prompt empiric coverage for staphylococci and streptococci: PO abx acceptable for mild presentation; <b class="calibre4">vancomycin</b> if ill appearing; broaden spectrum based on risk factors</p>
<p class="bl"><span class="sbl">•</span> Modify antibiotics based on Gram stain, culture results, &amp; clinical course. Duration of Rx is 1–4 wks. <b class="calibre4">Serial aspirations</b> every 1–3 d until sterile or no reaccumulation of fluid.</p>
<p class="bl"><span class="sbl">•</span> Surgery if unable to drain bursa through aspiration, evidence of foreign body or necrosis, recurrent/refractory bursitis w/ concern for infxn of adjacent structures</p>
<h2 class="ct"><a id="h105" class="calibre7"></a><a id="page_8-11" class="calibre7"></a><a href="part0002.html#rh116" class="calibre7">CONNECTIVE TISSUE DISEASES</a></h2>
<p class="imagef"><img src="../images/00127.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Centr, centromere; IM, inflammatory myopathies; RF, rheumatoid factor; Sm, Smith; SSc, systemic sclerosis; (<i class="calibre3">Primer on the Rheumatic Diseases</i>, 12th ed., 2001; <i class="calibre3">Lancet</i> 2013;382:797)</p>
<p class="bl"><span class="sbl">•</span> Only order auto-Ab testing if clinical suspicion for CTD, the presence of auto-Ab without characteristic clinical findings ≠ diagnosis, and auto-Ab do not define a particular CTD</p>
<p class="bl"><span class="sbl">•</span> Overlap syndromes may be reflected by multiple autoantibodies</p>
<p class="cst"><i class="calibre3">see “Systemic Lupus Erythematosus” and “Rheumatoid Arthritis” for those diseases</i></p>
<p class="h">S<small class="calibre30">YSTEMIC</small> S<small class="calibre30">CLEROSIS</small> <small class="calibre30">AND</small> S<small class="calibre30">CLERODERMA</small> D<small class="calibre30">ISORDERS</small></p>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">Best Pract Res Clin Rheumatol</i> 2010;24:857)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Scleroderma</b> refers to the presence of tight, thickened skin</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Localized scleroderma:</b> <i class="calibre3">morphea</i> (plaques of fibrotic skin), <i class="calibre3">linear</i> (fibrotic bands), “<i class="calibre3">en coup de saber</i>” (linear scleroderma on one side of scalp and forehead ≈ saber scar)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systemic sclerosis (SSc)</b> = scleroderma + internal organ involvement</p>
<p class="bl1">SSc w/ <i class="calibre3">limited cutaneous disease:</i> formerly CREST syndrome (see below)</p>
<p class="bl1">SSc w/ <i class="calibre3">diffuse cutaneous disease:</i> often rapidly progressive disorder affecting skin</p>
<p class="bl1">SSc <i class="calibre3">sine scleroderma</i> (visceral disease without skin involvement, rare)</p>
<p class="bl"><span class="sbl">•</span> Peak onset of SSc between <b class="calibre4">ages 30–50;</b> ♀ &gt; ♂ (7:1); African American &gt; white</p>
<p class="bl"><span class="sbl">•</span> 1–2/100,000 annual incidence of systemic disease in the U.S.</p>
<p class="bl"><span class="sbl">•</span> Pathogenesis: endothelial injury → ROS production → oxidative stress → perivascular inflammation → fibrosis. Cytokines, growth factors, genetics, environ. factors + antibodies (against PDGF receptor, endo. cells, fibroblasts) all contribute <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:1989)</span>.</p>
<p class="h2a">ACR/EULAR SSc classification criteria <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2013;72:1747)</span></p>
<p class="bl"><span class="sbl">•</span> Sufficient for dx: skin thickening of fingers of both hands extending proximal to MCPs</p>
<p class="bl"><span class="sbl">•</span> Other items considered in criteria: Raynaud’s, SSc-related auto-Ab, pulm hypertension (PHT) and/or ILD, abnormal nailfold capillaries, telangiectasia, fingertip lesions (ulcers, scars), skin thickening limited to fingers (not beyond MCPs)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rule out other causes</b> of thickened skin: diabetes (scleredema), scleromyxedema, toxin, hypothyroidism, nephrogenic systemic fibrosis, eosinophilic fasciitis, amyloidosis, GVHD</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre36"/>
<col class="calibre27"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3">
<p class="tabheadc">Clinical Manifestations of Systemic Sclerosis <span class="tfont1">(<i class="calibre3">Lancet</i> 2017;390:1685)</span></p>
</td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Skin</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Tightening and thickening of extremities, face, trunk (bx not req for dx)</p>
<p class="tab">“Puffy” hands, carpal tunnel syndrome, sclerodactyly</p>
<p class="tab">Nailfold capillary dilatation &amp; dropout</p>
<p class="tab">Immobile, pinched, “mouse-like” facies and “purse-string” mouth</p>
<p class="tab">Calcinosis cutis (subcutaneous calcification), telangiectasias</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Arteries</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">Raynaud’s phenomenon</b> (80%); digital or visceral ischemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal</b></p></td>
<td class="bg0-b" colspan="2"><p class="tabh"><b class="calibre4">Scleroderma renal crisis (SRC)</b> = accelerated development of HTN (<i class="calibre3">relative</i> ↑ <i class="calibre3">in BP as compared with Pt’s baseline BP</i>), MAHA</p>
<p class="tab">Urine sed. typically bland; “onion-skin” hypertrophy of capillaries</p>
<p class="tabh">Affects 5–10% of Pts, 66% w/in 1<sup class="calibre35">st</sup> yr (<i class="calibre3">Rheum</i> 2009;48:iii32); &gt;15 mg/d prednisone and RNA Pol III Ab a/w ↑ risk of developing SRC</p>
<p class="tab">Poor prognosis w/ 50% mortality</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GI</b> (&gt;80% of Pts)</p></td>
<td class="bg0-b" colspan="2"><p class="tab">GERD and erosive esophagitis</p>
<p class="tab">Esophageal dysmotility → dysphagia, odynophagia, aspiration</p>
<p class="tab">Gastric dysmotility → early satiety and gastric outlet obstruction</p>
<p class="tab">Small intestinal dysmotility → malabsorption, bact overgrowth, bloating</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Musculoskel</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Arthralgias/arthritis; myositis; joint contractures; tendon friction rubs</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiac</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Myocardial fibrosis; pericardial effusion; conduction abnormalities; CAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulmonary</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">Pulmonary fibrosis</b> (typically develops w/in 4 y); <b class="calibre4">pulmonary arterial hypertension</b> (typically develops after many yrs); #1 cause of mortality</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Endocrine</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Amenorrhea and infertility common; thyroid fibrosis ± hypothyroidism</p></td>
</tr>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><a id="page_8-12" class="calibre1"></a><p class="tabheadc">SSc Subgroup Comparison</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Limited</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Diffuse</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">General</b></p></td>
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-b"><p class="tab">Fatigue, weight loss</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Skin</b></p></td>
<td class="bg0-br"><p class="tabh">Thickening on extremities <i class="calibre3">distal</i> to elbows/knees and <i class="calibre3">face</i> only</p></td>
<td class="bg0-b"><p class="tabh">Thickening of distal <i class="calibre3">and proximal</i> ext, face <i class="calibre3">and trunk</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulmonary</b></p></td>
<td class="bg0-br"><p class="tab">PAH (rapidly progressive) &gt; fibrosis</p></td>
<td class="bg0-b"><p class="tab">Fibrosis &gt; PAH</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GI</b></p></td>
<td class="bg0-br"><p class="tab">Primary biliary cirrhosis</p></td>
<td class="bg0-b"><p class="tab"> </p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal</b></p></td>
<td class="bg0-br"><p class="tab">SRC later in disease course</p></td>
<td class="bg0-b"><p class="tab">SRC earlier &amp; more common</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiac</b></p></td>
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-b"><p class="tab">Restrictive cardiomyopathy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Other</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">CREST syndrome</b> = <b class="calibre4">C</b>alcinosis, <b class="calibre4">R</b>aynaud’s, <b class="calibre4">E</b>sophageal dysmotility, <b class="calibre4">S</b>clerodactyly, <b class="calibre4">T</b>elangiectasias</p></td>
<td class="bg0-b"><p class="tab">Raynaud’s</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Antibodies</b></p></td>
<td class="bg0-br"><p class="tab">Centromere (10–40%)</p></td>
<td class="bg0-b"><p class="tab">Scl 70, RNA-Pol III (40%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Prognosis</b></p></td>
<td class="bg0-r"><p class="tab">Survival &gt;70% at 10 y</p></td>
<td class="bg"><p class="tab">Survival 40–60% at 10 y</p></td>
</tr>
</table>
<p class="h2a">Diagnostic studies &amp; monitoring <span class="s">(<i class="calibre3">Semin Arthritis Rheum</i> 2005;35:35)</span></p>
<p class="bl"><span class="sbl">•</span> Autoantibodies: &gt;95% Pts w/ auto-Ab; generally mutually exclusive</p>
<p class="bl1">⊕ <b class="calibre4">anti-Scl-70</b> (anti-topoisomerase 1): a/w diffuse SSc; ↑ risk pulm fibrosis</p>
<p class="bl1">⊕ <b class="calibre4">anticentromere:</b> a/w limited SSc; ↑ risk of severe digit ischemia and PHT</p>
<p class="bl1">⊕ <b class="calibre4">anti-RNA-Pol III:</b> a/w diffuse SSc; ↑ risk renal crisis; a/w cancer</p>
<p class="bl1">⊕ ANA (&gt;90%), ⊕ RF (30%), ⊕ anti-U1-RNP a/w overlap syndrome</p>
<p class="bl1">Other: anti-Th/To (a/w limited SSc), U3-RNP (a/w ILD), PmScl (polymyositis-SSc overlap)</p>
<p class="bl"><span class="sbl">•</span> CXCL4 levels reported to help diagnose disease and be correlated w/ degree of lung &amp; skin fibrosis and disease progression but awaits validation <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:433)</span></p>
<p class="bl"><span class="sbl">•</span> At baseline: ✔ BUN/Cr &amp; UA for proteinuria, PFTs (spirometry, lung volumes, D<sub class="calibre8">L</sub>CO), high-res chest CT (if diffuse disease), TTE (RVSP for PHT), RHC if ↑ RVSP or suspect PHT</p>
<p class="bl"><span class="sbl">•</span> Annual PFTs; TTE q1–2y</p>
<p class="bl"><span class="sbl">•</span> Skin bx not routine, but helpful to assess other possible causes for skin thickening</p>
<p class="bl"><span class="sbl">•</span> ↑ risk of malignancy (esp. lung cancer) compared to general population, ∴ must be vigilant</p>
<p class="bl"><span class="sbl">•</span> Frequent (eg, daily) BP ✔ to monitor for HTN suggestive of scleroderma renal crisis</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Arthritis Rheumatol</i> 2018;70:1820)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Minimize steroid exposure to reduce risk of renal crisis</i></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Pulmonary</i> fibrosis: <b class="calibre4">MMF</b> <span class="s1r">(<i class="calibre3">Lancet Respir Med</i> 2016;4:708)</span> vs. <b class="calibre4">cyclophosphamide</b> (<small class="calibre40">NEJM</small> 2006;354:2655); MMF + perfinidone under evaluation <span class="s1r">(<i class="calibre3">Rheum Dis Clin NA</i> 2015;41:237)</span></p>
<p class="bl1">PAH: <b class="calibre4">pulmonary vasodilators</b> (see “Pulm Hypertension”), early Rx a/w better outcomes</p>
<p class="bl"><span class="sbl">•</span> Renal crisis: <b class="calibre4">ACEI</b> (not ARB) for Rx, not prophylaxis <span class="s1r">(<i class="calibre3">Semin Arthritis Rheum</i> 2015;44:687)</span></p>
<p class="bl"><span class="sbl">•</span> GI: PPI and/or H2-blockers for GERD; antibiotics for malabsorption</p>
<p class="bl1">hypomotility: metoclopramide or erythromycin; nonoperative Rx of pseudo-obstruction</p>
<p class="bl"><span class="sbl">•</span> Cardiac: NSAIDs ± colchicine superior to steroids for pericarditis</p>
<p class="bl"><span class="sbl">•</span> Arthritis: acetaminophen, NSAIDs, hydroxychloroquine, MTX</p>
<p class="bl"><span class="sbl">•</span> Myositis: MTX, AZA, steroids</p>
<p class="bl"><span class="sbl">•</span> Skin: PUVA for morphea. Pruritus: emollients, topical or oral steroids (↓ dose). Fibrosis: MTX or MMF ? efficacy <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2017;76:1207; <i class="calibre3">Int J Rheum Dis</i> 2017;20:481)</span></p>
<p class="bl"><span class="sbl">•</span> Auto-HSCT promising for severe disease <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:35)</span></p>
<p class="h">I<small class="calibre30">NFLAMMATORY</small> M<small class="calibre30">YOPATHIES</small></p>
<p class="h2a">Definition &amp; epidemiology <span class="s">(<i class="calibre3">JAMA</i> 2013;305:183; <i class="calibre3">NEJM</i> 2015;372:1734)</span></p>
<p class="bl"><span class="sbl">•</span> All lead to skeletal muscle inflammation &amp; weakness, variable extramuscular involvement</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polymyositis</b> (PM): idiopathic diffuse polymyopathy, onset typically 40s–50s; ♀ &gt; ♂</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dermatomyositis</b> (DM): similar to PM; also occurs in childhood, but differentiated from other myopathies by skin manifestations; <b class="calibre4">malignancy a/w PM</b> (10%) <b class="calibre4">and DM</b> (24%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Necrotizing autoimmune myositis</b> (NM): usually in adults; risk factors include statin exposure ⊕ anti-HMGCR), CTD, malignancy, and rarely viral infection</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inclusion body myositis</b> (IBM): onset after age 50; ♂ &gt; ♀; often <i class="calibre3">misdiagnosed as PM</i></p>
<p class="bl"><span class="sbl">•</span> DDx: drug-induced toxic myopathy (statins, cocaine, steroids, colchicine); infxn (HIV, EBV, CMV); metabolic (hypothyroid, hypo-K, hypo-Ca); neuromuscular dis. (eg, myasthenia gravis); glycogen storage disease; mitochondrial cytopathy; muscular dystrophy</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">NEJM</i> 2015;372:1734)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Muscle weakness:</b> gradual (wks → mos) except in NM, progressive and painless</p>
<p class="bl1">DM/PM/NM: <b class="calibre4">proximal and symmetric</b><i class="calibre3">;</i> difficulty climbing stairs, arising from chairs, brushing hair; fine motor skills (eg, buttoning) lost late</p>
<p class="bl1">IBM may be <i class="calibre3">asymmetric and distal</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Skin findings in dermatomyositis:</b> may precede myositis by mos to yrs</p>
<p class="bl1"><a id="page_8-13" class="calibre1"></a><i class="calibre3">Gottron’s papules</i>: seen in &gt;80% of Pts &amp; pathognomonic; violaceous, often scaly, areas symmetrically over dorsum of PIP and MCP joints, elbows, patellae, medial malleoli</p>
<p class="bl1"><i class="calibre3">Heliotrope rash</i>: purplish discoloration over upper eyelids ± periorbital edema</p>
<p class="bl1"><i class="calibre3">Poikiloderma</i>: red or purple rash w/ areas of hyper and hypopigmentation mostly on sun-exposed areas; upper back (shawl sign), neck &amp; chest (V sign), and hips (Holster sign)</p>
<p class="bl1"><i class="calibre3">Mechanic’s hands</i>: cracking, fissuring radial side of digits and can include pigmentation along palmar crease; a/w antisynthetase syndrome; also seen in PM</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pulmonary:</b> acute alveolitis, <b class="calibre4">interstitial lung disease</b>; resp muscle weakness; aspiration</p>
<p class="bl1"><i class="calibre3">Antisynthetase syndrome</i>: acute onset DM or PM w/ <b class="calibre4">rapidly progressive ILD</b>, fever, weight loss, Raynaud’s, mechanic’s hands, arthritis; most commonly <b class="calibre4">anti-Jo-1</b> ⊕</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiac:</b> (33%): often asx; conduction abnl; myo/pericarditis; HF uncommon; ↑ CK-MB/Tn</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">GI:</b> dysphagia, aspiration</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polyarthralgias or polyarthritis:</b> usually early, nonerosive; small joints &gt; large joints</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Raynaud’s</b> (30%, DM and overlap CTD) w/ dilatation &amp; dropout of nail bed capillaries</p>
<p class="h2a"><a id="page_8-14" class="calibre1"></a><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">CK</b> (rarely &gt;100,000 U/L, can be ↑↑↑ in NM), aldolase, SGOT, LDH; ± ↑ ESR &amp; CRP</p>
<p class="bl"><span class="sbl">•</span> Autoantibodies: ⊕ ANA (&gt;75%) <span class="s1r">(<i class="calibre3">Curr Rheumatol Rep</i> 2013;15:335)</span></p>
<p class="bl1">⊕ <b class="calibre4">anti-Jo-1</b> (25%): most common specific Ab; a/w antisynthetase syndrome</p>
<p class="bl1">⊕ anti-Mi-2 (DM &gt; PM 15-20%) is a/w disease that responds well to steroids</p>
<p class="bl1">⊕ anti-SRP is a/w NM, poor Rx response; ⊕ anti-HMGCR in NM a/w statin exposure</p>
<p class="bl"><span class="sbl">•</span> Consider <b class="calibre4">EMG</b> (↑ spontaneous activity, ↓ amplitude, polyphasic potentials w/ contraction) or <b class="calibre4">MRI</b> (muscle edema, inflammation, atrophy) for evaluation; may guide biopsy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pathology and muscle biopsy:</b> all with interstitial mononuclear infiltrates, muscle fiber necrosis, degeneration &amp; regeneration (required for definitive diagnosis)</p>
<p class="bl1">PM: <i class="calibre3">T cell–mediated muscle injury;</i> endomysial inflam. surrounds non-necrotic fibers</p>
<p class="bl1">DM: <i class="calibre3">immune complex deposition in blood vessels with complement</i> activation; perimysial, perivascular inflam (B &amp; CD4 T cells), complement in vessels.</p>
<p class="bl1">NM: <i class="calibre3">necrotic fibers w/ macrophages</i></p>
<p class="bl1">IBM: <i class="calibre3">T cell–mediated muscle injury, vacuole formation;</i> same as PM with eosinophilic inclusions and rimmed vacuoles (EM)</p>
<p class="h2a">Treatment (PM &amp; DM, no effective treatment for IBM) <span class="s1r">(<i class="calibre3">Autoimmun Rev</i> 2011;11:6)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Steroids</b> (prednisone 1 mg/kg); MTX or AZA early if mod/severe or taper fails (2–3 mo)</p>
<p class="bl"><span class="sbl">•</span> For resistant (30–40%) or severe disease: AZA/MTX combo, IVIg (DM ± PM), rituximab <span class="s1r">(<i class="calibre3">Arthritis Rheum</i> 2013;65:314)</span>, MMF, cyclophosphamide (esp. if ILD or vasculitis)</p>
<p class="bl"><span class="sbl">•</span> IVIg w/ pulse steroids acutely for life-threatening esophageal or resp muscle involvement</p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">for occult malignancy</b> (esp. if DM); monitor respiratory muscle strength with spirometry</p>
<p class="bl"><span class="sbl">•</span> NM: discontinue statin if taking; steroids + MTX or IVIG if needed (<small class="calibre40">MUSCLE NERVE</small> 2010;41:185)</p>
<p class="image1"><img src="../images/00128.jpeg" alt="" class="calibre2"/></p>
<p class="h">S<small class="calibre30">JÖGREN’S</small> S<small class="calibre30">YNDROME</small> <span class="s1">(<i class="calibre22">NEJM</i> 2018;378:931)</span></p>
<p class="h2a">Definition &amp; epidemiology</p>
<p class="bl"><span class="sbl">•</span> Chronic dysfxn of <b class="calibre4">exocrine glands</b> (eg, salivary/lacrimal) due to lymphoplasmacytic infiltration, extraglandular manifestations common in primary form</p>
<p class="bl"><span class="sbl">•</span> Can be primary or secondary (a/w RA, scleroderma, SLE, PM, hypothyroidism, HIV)</p>
<p class="bl"><span class="sbl">•</span> More prevalent in ♀ than ♂; typically presents between 40 &amp; 60 y of age</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dry eyes</b> (keratoconjunctivitis sicca): ↓ tear production; burning, scratchy sensation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dry mouth</b> (xerostomia): difficulty speaking/swallowing, <b class="calibre4">dental caries</b>, xerotrachea, thrush</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Parotid gland enlargement:</b> intermittent, painless, typically bilateral</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vaginal dryness</b> and <b class="calibre4">dyspareunia</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Recurrent nonallergic rhinitis/sinusitis</b> due to upper airway gland involvement</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Extraglandular manifestations:</b> arthritis, interstitial nephritis (40%), type I RTA (20%), cutaneous vasculitis (25%), neuropathies (10%), PNS or CNS disease, ILD, PBC</p>
<p class="bl"><span class="sbl">•</span> ↑ risk of lymphoproliferative disorders (~50× ↑ risk of lymphoma and WM in 1° Sjögren’s)</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Autoantibodies: ⊕ ANA (95%), ⊕ RF (75%)</p>
<p class="bl1">Primary Sjögren’s: ⊕ <b class="calibre4">anti-Ro</b> (anti-SS-A, 56%) and/or ⊕ <b class="calibre4">anti-La</b> (anti-SS-B, 30%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Schirmer test:</b> filter paper in palpebral fissures to assess tear production</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rose-Bengal</b> staining: dye that reveals devitalized epithelium of cornea/conjunctiva</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ocular staining score:</b> substitute for Rose-Bengal staining to determine degree of keratoconjunctivitis sicca using fluorescein and lissamine green</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biopsy</b> (minor salivary, labial, lacrimal, or parotid gland): lymphocytic infiltration</p>
<p class="h2a">Classification criteria (≥4 points 96% Se &amp; 95% Sp; <i class="calibre3">Arthritis Rheum</i> 2016;69:35)</p>
<p class="bl"><span class="sbl">•</span> 3 points: ⊕ anti-Ro; labial saliv. gland bx w/ lymphocytic sialadenitis &amp; score ≥1 foci/4mm<sup class="calibre15">2</sup></p>
<p class="bl"><span class="sbl">•</span> 1 point: abnormal ocular staining score ≥5; Schirmer’s test ≤5 mm/5 min; unstimulated salivary flow rate of ≤0.1 mL/min</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Arth Res Ther</i> 2013;15:R172)</span></p>
<p class="bl"><span class="sbl">•</span> Ocular: artificial tears, cyclosporine eyedrops, autologous tears</p>
<p class="bl"><span class="sbl">•</span> Oral: sugar-free gum, lemon drops, saliva substitute, hydration, pilocarpine, cevimeline</p>
<p class="bl"><span class="sbl">•</span> Systemic: depends on extraglandular manifest.; NSAIDs, steroids, DMARDs, rituximab</p>
<p class="h">M<small class="calibre30">IXED</small> C<small class="calibre30">ONNECTIVE</small> T<small class="calibre30">ISSUE</small> D<small class="calibre30">ISEASE</small> (MCTD)</p>
<p class="h2a">Definition <span class="s">(<i class="calibre3">Best Pract Res Clin Rheumatol</i> 2012;26:61)</span></p>
<p class="bl"><span class="sbl">•</span> Features of <b class="calibre4">SLE</b>, <b class="calibre4">systemic sclerosis</b>, and/or <b class="calibre4">polymyositis</b> that appear gradually over years and often evolve to a dominant phenotype of SLE or systemic sclerosis</p>
<p class="bl"><span class="sbl">•</span> Different from undifferentiated CTD (UCTD): non-specific symptoms that fail to meet criteria for any CTD; 30% go on to develop CTD over 3–5 y (usually SLE)</p>
<p class="h2a">Clinical &amp; laboratory manifestations (variable clinical course)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Raynaud’s phenomenon</b> typical presenting symptom (75–90%); see below</p>
<p class="bl"><span class="sbl">•</span> Hand edema (“puffy hands”), sclerodactyly, RA-like <b class="calibre4">arthritis</b> w/o erosions, polyarthralgias</p>
<p class="bl"><span class="sbl">•</span> Pulmonary involvement (85%) with <b class="calibre4">pulmonary hypertension</b>, fibrosis</p>
<p class="bl"><span class="sbl">•</span> Pericarditis most frequent cardiovascular manifestation; GI: dysmotility (70%)</p>
<p class="bl"><span class="sbl">•</span> Membranous &amp; mesangial GN common (25%); low risk for renal HTN crisis or severe GN</p>
<p class="bl"><span class="sbl">•</span> ⊕ ANA (&gt;95%); ⊕ RF (50%); requires ⊕ <b class="calibre4">anti-U1-RNP</b> but <i class="calibre3">not</i> specific (seen in ~50% SLE)</p>
<p class="h2a">Treatment: <span class="s2">As per specific rheumatic diseases detailed above</span></p>
<p class="h">R<small class="calibre30">AYNAUD</small>’<small class="calibre30">S</small> P<small class="calibre30">HENOMENON</small></p>
<p class="h2a">Clinical manifestations &amp; diagnosis <span class="s">(<i class="calibre3">NEJM</i> 2016;375:556)</span></p>
<p class="bl"><span class="sbl">•</span> Episodic, reversible digital ischemia, triggered by cold temp, or stress, classically: <b class="calibre4">blanching</b> (white, ischemia) → <b class="calibre4">cyanosis</b> (blue, hypoxia) → <b class="calibre4">rubor</b> (red, reperfusion); color Δ usually well demarcated; affects fingers, toes, ears, nose</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre27"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Primary vs. Secondary Raynaud’s Phenomenon</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead"> </p></td>
<td class="bg0-br"><p class="tabhead">Primary (80–90%)</p></td>
<td class="bg0-b"><p class="tabhead">Secondary (<b class="calibre4">1</b>0–20%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Vessel wall</b></p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">Functionally</i> abnl</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Structurally</i> abnl</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
<td class="bg0-br"><p class="tab">Idiopathic; however, can be exacerbated by comorbid conditions, including HTN, athero, CAD, DM</p></td>
<td class="bg0-b"><p class="tab">SSc, SLE, PM-DM, MCTD, Sjögren’s, RA</p>
<p class="tab">Arterial dis (athero, Buerger’s), trauma</p>
<p class="tab">Heme (cyro, Waldenström’s, APLAS)</p>
<p class="tab">Drugs (ergopeptides, estrogens, cocaine)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Epidem.</b></p></td>
<td class="bg0-br"><p class="tab">20–40 y; ♀ &gt; ♂ (5:1)</p></td>
<td class="bg0-b"><p class="tab">&gt;35 y</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Clinical</b></p></td>
<td class="bg0-br"><p class="tab">Mild, <i class="calibre3">symm.</i> episodic attacks</p>
<p class="tab"><i class="calibre3">No tissue injury</i>, PVD, or systemic sx<i class="calibre3">; spares thumb</i></p></td>
<td class="bg0-b"><p class="tab">Severe, <i class="calibre3">asymm</i>. attacks; <b class="calibre4">tissue ischemia &amp; injury</b> (eg, digital ulcers); can be assoc w/ systemic sx; may affect thumb or prox limbs</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Auto Ab</b></p></td>
<td class="bg0-br"><p class="tab">CTD antibodies</p></td>
<td class="bg0-b"><p class="tab">Depends on etiology, CTD Ab often ⊕</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Nailfold</b></p></td>
<td class="bg0-r"><p class="tab">Normal capillaroscopy</p></td>
<td class="bg"><p class="tab"><b class="calibre4">Dropout and enlarged or distorted loops</b></p></td>
</tr>
</table>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Curr Opin Rheumatol</i> 2011;23:555; <i class="calibre3">BMJ</i> 2012;344:e289)</span></p>
<p class="bl"><span class="sbl">•</span> All: avoid cold, maintain warmth of digits &amp; body; avoid cigarettes, sympathomimetics, caffeine &amp; trauma; abx for infected ulceration</p>
<p class="bl"><span class="sbl">•</span> Mild–mod: <b class="calibre4">long-acting CCB</b>, topical nitrates, SSRI, ARB, α-blockers, ASA/clopidogrel</p>
<p class="bl"><span class="sbl">•</span> Severe: PDE inhibitors, anti-ET-1 receptor (if ulcers esp. w/ PHT), digital sympathectomy</p>
<p class="bl"><span class="sbl">•</span> Digit-threatening: IV prostaglandins, digital sympathectomy, ± anticoagulation</p>
<h2 class="ct"><a id="h106" class="calibre7"></a><a id="page_8-15" class="calibre7"></a><a href="part0002.html#rh117" class="calibre7">SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)</a></h2>
<p class="cst"><i class="calibre3">Multisystem inflammatory autoimmune disease with a broad spectrum of clinical manifestations in association with antinuclear antibody (ANA) production</i></p>
<p class="h2a">Epidemiology <span class="s">(<i class="calibre3">Lancet</i> 2014;384:1878)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence 15–50/100,000; predominantly affects women 2<sup class="calibre15">nd</sup> to 4<sup class="calibre15">th</sup> decade</p>
<p class="bl"><span class="sbl">•</span> ♀:♂ ratio = 8:1; African American:Caucasian ratio = 4:1</p>
<p class="bl"><span class="sbl">•</span> Complex genetics; some HLA association; rarely C1q &amp; C2 deficiency</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre36"/>
<col class="calibre27"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Clinical Criteria</p></td>
<td class="bg0-br"><p class="tabheadc">SLICC Classification Criteria<a id="st16" class="calibre1"></a><a href="part0013.html#sst16" class="calibre1">*</a></p></td>
<td class="bg0-b"><p class="tabheadc">Other Clinical Features</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Constit</b> (84%)</p></td>
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-b"><p class="tab">Fever, malaise, anorexia, ↓ wt</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cutaneous/Oral/ Ophthalmologic</b></p>
<p class="tab">(81%)</p></td>
<td class="bg0-br">
<p class="num-t"><span class="snum-t">  <b class="calibre4">1.</b></span> <b class="calibre4">Acute or subacute cutaneous changes</b></p>
<p class="num-t"><span class="snum-t">  <b class="calibre4">2.</b></span> <b class="calibre4">Chronic cutaneous changes</b></p>
<p class="num-t"><span class="snum-t">  <b class="calibre4">3.</b></span> <b class="calibre4">Oral or nasal ulcers</b></p>
<p class="num-t"><span class="snum-t">  <b class="calibre4">4.</b></span> <b class="calibre4">Nonscarring alopecia</b></p></td>
<td class="bg0-b"><p class="tabh">Malar rash (spares nasolabial folds), discoid rash (papules w/ keratosis &amp; plugging), bullous SLE, urticaria, TEN</p>
<p class="tab">Photosens. (n/v, rash, fever)</p>
<p class="tabh">Vasculitis, panniculitis (lupus profundus)</p>
<p class="tab">Raynaud’s, nailfold cap Δs,</p>
<p class="tab">Sicca syndrome</p>
<p class="tab">Conjunctivitis, episcleritis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Musculoskeletal</b></p>
<p class="tab">(85–95%)</p></td>
<td class="bg0-br"><p class="num-t"><span class="snum-t">  <b class="calibre4">5.</b></span> <b class="calibre4">Joint disease:</b> synovitis or tenderness &amp; morning stiffness involving ≥2 joints</p></td>
<td class="bg0-b"><p class="tab">Arthralgias and myalgias</p>
<p class="tab">Avascular necrosis of bone</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiopulmonary</b></p>
<p class="tab">(33%)</p></td>
<td class="bg0-br"><p class="num-t"><span class="snum-t">  <b class="calibre4">6.</b></span> <b class="calibre4">Serositis:</b> pleuritis (37%) or pleural effusion, pericarditis (29%) or pericardial effusion</p></td>
<td class="bg0-b"><p class="tabh">Pneumonitis, IPF, shrinking lung, PAH, DAH</p>
<p class="tab">Myocarditis, CAD</p>
<p class="tab">Libman-Sacks endocarditis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal</b></p>
<p class="tab">(77%)</p></td>
<td class="bg0-br"><p class="num-t"><span class="snum-t">  <b class="calibre4">7.</b></span> <b class="calibre4">Proteinuria</b> (&gt;0.5 g/dL) or <b class="calibre4">RBC casts</b></p></td>
<td class="bg0-b"><p class="tab">Nephrotic syndrome</p>
<p class="tab">Lupus nephritis (qv)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Neurologic</b></p>
<p class="tab">(54%)</p></td>
<td class="bg0-br"><p class="num-t"><span class="snum-t">  <b class="calibre4">8.</b></span> <b class="calibre4">Seizures or psychosis</b> w/o other cause</p></td>
<td class="bg0-b"><p class="tab">Cognitive dysfxn, stroke, cranial or periph neuropathies, transverse myelitis, mononeuritis multiplex</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GI</b></p>
<p class="tab">(~30%)</p></td>
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-b"><p class="tab">Serositis (peritonitis, ascites)</p>
<p class="tab">Vasculitis (bleeding, perf.)</p>
<p class="tab">Hepatitis, pancreatitis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hematologic</b></p></td>
<td class="bg0-br"><p class="num-t"><span class="snum-t">  <b class="calibre4">9.</b></span> <b class="calibre4">Hemolytic anemia</b></p>
<p class="num-t"><span class="snum-t"><b class="calibre4">10.</b></span> <b class="calibre4">Leukopenia</b> (&lt;4000/mm<sup class="calibre35">3</sup>) <i class="calibre3">or</i> <b class="calibre4">lymphopenia</b> (&lt;1000/mm<sup class="calibre35">3</sup>)</p>
<p class="num-t"><span class="snum-t"><b class="calibre4">11.</b></span> <b class="calibre4">Thrombocytopenia</b> (&lt;100,000/mm<sup class="calibre35">3</sup>)</p></td>
<td class="bg0-b"><p class="tab">Anemia of chronic disease</p>
<p class="tabh">Antiphospholipid synd (VTE w/ ⊕ ACL Ab, lupus anticoag, and/or B2GPI Ab)</p>
<p class="tab">Splenomegaly, LAN</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Immunologic</b></p></td>
<td class="bg0-r"><p class="num-t"><span class="snum-t"><b class="calibre4">12.</b></span> ⊕ ANA; <b class="calibre4">13.</b> ⊕ anti-ds-DNA</p>
<p class="num-t"><span class="snum-t"><b class="calibre4">14.</b></span> ⊕ anti-Sm; <b class="calibre4">15.</b> ⊕ APLA</p>
<p class="num-t"><span class="snum-t"><b class="calibre4">16.</b></span> ↓ Complement: C3, C4, CH50</p>
<p class="num-t"><span class="snum-t"><b class="calibre4">17.</b></span> ⊕ Direct Coombs’ (w/o #9)</p></td>
<td class="bg"><p class="tab">↑ ESR/CRP, ⊕ anti-Ro/La,</p>
<p class="tab">⊕ anti-RNP, ⊕ RF,</p>
<p class="tab">⊕ anti-CCP</p></td>
</tr>
</table>
<p class="tsr"><a id="sst16" class="calibre1"></a><a href="part0013.html#st16" class="calibre1">*</a>Expert opinion, not dx criteria for SLE: ≥4/17 SLICC criteria, including ≥1 clinical &amp; ≥1 immunologic, <i class="calibre3">or</i> bx proven SLE nephritis w/ ⊕ ANA or anti-ds-DNA (<i class="calibre3">Arth Rheum</i> 2012;64:2677)</p>
<p class="image1"><img src="../images/00129.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_8-16" class="calibre1"></a>Workup</p>
<p class="bl"><span class="sbl">•</span> Autoantibodies: ANA, if ⊕ → ✔ anti-ds-DNA, anti-Sm, anti-Ro, anti-La, anti-U1-RNP</p>
<p class="bl"><span class="sbl">•</span> CBC, APLA (⊕ in 20–40%; ACL, B2GP1, lupus anticoagulant), total complement, C3 &amp; C4</p>
<p class="bl"><span class="sbl">•</span> Lytes, BUN, Cr, U/A, urine sed, spot microalb:Cr ratio or 24-h urine for CrCl and protein</p>
<p class="bl"><span class="sbl">•</span> If ↓ GFR, active sediment, hematuria, or proteinuria (&gt;0.5 g/dL) → renal bx to guide Rx</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre49"/>
<col class="calibre50"/>
<col class="calibre49"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Treatment of SLE</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Curr Rheumatol Rep</i></span> <span class="tfont1">20</span><span class="tfont1">11</span><span class="tfont1">;</span><span class="tfont1">1</span><span class="tfont1">3:308;</span> <span class="tfont1"><i class="calibre3">Arthritis Care Res</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;67:</span><span class="tfont1">1</span><span class="tfont1">237)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Drug</p></td>
<td class="bg0-br"><p class="tabhead">Indication</p></td>
<td class="bg0-b"><p class="tabhead">Adverse Effects</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hydroxychloroquine (HCQ)</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">All Pts b/c</b> ↓ <b class="calibre4">flares</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">1</span><span class="tfont1">99</span><span class="tfont1">1</span><span class="tfont1">;324:</span><span class="tfont1">1</span><span class="tfont1">50)</span>; monoRx for arthritis, serositis, skin disease</p></td>
<td class="bg0-b"><p class="tab">Retinal damage (&lt;1%)</p>
<p class="tab">Stevens-Johnson; myopathy <i class="calibre3">Not immunosuppressive</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">NSAIDs</b></p></td>
<td class="bg0-br"><p class="tab">Arthritis, myalgias, serositis</p></td>
<td class="bg0-b"><p class="tab">Gastritis, UGIB, renal failure</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Corticosteroids</b></p></td>
<td class="bg0-br"><p class="tab">Low dose (10–15 mg) for arthritis, serositis; high-dose (1 mg/kg) ± pulse (1 g × 3 d) for major dis (eg, renal, CNS, heme)</p></td>
<td class="bg0-b"><p class="tab">Adrenal suppression, DM, cataracts, osteopenia, avascular necrosis of bone, myopathy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mycophenolate (MMF)</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Nephritis</b> (induction/maint)</p>
<p class="tab">Nonrenal refractory to HCQ</p></td>
<td class="bg0-b"><p class="tab">Cytopenias, ↑ LFTs, diarrhea, teratogen</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cyclophosphamide (CYC)</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Nephritis</b></p>
<p class="tab"><b class="calibre4">CNS disease</b> (induction, minimize exposure)</p></td>
<td class="bg0-b"><p class="tab">Cytopenias, infertility, teratogen, myeloproliferative disorders, hemorrhagic cystitis, bladder cancer</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Azathioprine (AZA)</b></p></td>
<td class="bg0-br"><p class="tab">Nephritis (maintenance)</p>
<p class="tabh">Non-renal disease refractory to HCQ</p></td>
<td class="bg0-b"><p class="tab">Myelosuppression (✔TPMT), hepatotoxicity, teratogen lymphoproliferative disorders</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Methotrexate (MTX)</b></p></td>
<td class="bg0-br"><p class="tabh">Arthritis (preferred over MMF/AZA)</p>
<p class="tab">Skin disease &amp; serositis</p></td>
<td class="bg0-b"><p class="tab">Myelosuppression, alopecia, hepatotoxicity, stomatitis,</p>
<p class="tab">pneumonitis, teratogen</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cyclosporine (CsA)</b></p></td>
<td class="bg0-br"><p class="tab">Renal disease</p></td>
<td class="bg0-b"><p class="tab">Hyperplastic gums, HTN</p>
<p class="tab">hirsutism, CKD, anemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Belimumab</b></p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">3;368:</span><span class="tfont1">1</span><span class="tfont1">528)</span></p></td>
<td class="bg0-br"><p class="tab">Arthritis, serositis, skin disease (esp. if ⊕ ds-DNA or ↓ C3/C4)</p></td>
<td class="bg0-b"><p class="tab">B-cell depletion (&lt; RTX, different mechanism)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rituximab (RTX)</b></p></td>
<td class="bg0-br"><p class="tab">Refractory SLE, ITP, AIHA</p></td>
<td class="bg0-b"><p class="tab">Infusion reaction; serum sickness; PML</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Baricitinib</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;392:222)</span></p></td>
<td class="bg0-r"><p class="tab">Prelim data: 4 mg w/ efficacy in arthritis, skin disease</p></td>
<td class="bg"><p class="tab">Infections (zoster), ↑ LFTs, cytopenias, dyslipidemia</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre27"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Lupus Nephritis</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Arthritis Care Res</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">2;64:797)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Class</p></td>
<td class="bg0-br"><p class="tabhead">Presentation</p></td>
<td class="bg0-b"><p class="tabhead">Treatment (all benefit from HCQ)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">I: Min. mesangial</p></td>
<td class="bg0-br"><p class="tab">Normal U/A &amp; creatinine</p></td>
<td class="bg0-b"><p class="tab">No specific treatment</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">II: Mesangial prolif</p></td>
<td class="bg0-br"><p class="tab">Micro hematuria/proteinuria</p></td>
<td class="bg0-b"><p class="tab">No specific treatment ± ACEI</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">III: Focal prolif</p></td>
<td class="bg0-br"><p class="tab">Hematuria/proteinuria, ± HTN, ↓ GFR, ± nephrotic</p></td>
<td class="bg0-b" rowspan="2"><p class="tab">Induce: MMF <i class="calibre3">or</i> CYC + steroids</p>
<p class="tab">Maintenance: ? MMF &gt; AZA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">IV: Diffuse prolif</p></td>
<td class="bg0-b"><p class="tab">Hematuria/proteinuria and HTN, ↓ GFR, ± nephrotic</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">V: Membranous</p>
<p class="tab">(can coexist with class III or IV)</p></td>
<td class="bg0-br"><p class="tab">Proteinuria, nephrotic</p></td>
<td class="bg0-b"><p class="tab">ACEI</p>
<p class="tabh">If nephrotic-range proteinuria, induce w/ MMF + steroids</p>
<p class="tab">Maintenance: MMF superior to AZA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">VI: Adv. sclerotic</p></td>
<td class="bg0-r"><p class="tab">ESRD</p></td>
<td class="bg"><p class="tab">Renal replacement therapy</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Ann Rheum Dis</i> 2010;69:2083; <i class="calibre3">NEJM</i> 2004;350:971 &amp; 2005;353:2219 &amp; 2011;365:1886)</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">Arth Rheum</i> 2006;54:2550; <i class="calibre3">Rheum [Oxford]</i> 2016;55:252)</span></p>
<p class="bl"><span class="sbl">•</span> 5-y survival rate &gt;90%, 10-y survival rate &gt;80%</p>
<p class="bl"><span class="sbl">•</span> Leading causes of morbidity and mortality: <b class="calibre4">infection</b>, <b class="calibre4">renal failure</b>, neurologic and cardiovascular events; thrombotic complications <span class="s1r">(<i class="calibre3">Medicine</i> 2003;82:299)</span></p>
<p class="h2a">Drug-induced lupus (DLE) <span class="s">(<i class="calibre3">Drug Saf</i> 2011;34:357; <i class="calibre3">Curr Opin Rheumatol</i> 2012;24:182)</span></p>
<p class="bl"><span class="sbl">•</span> Many drugs: <b class="calibre4">procainamide</b>, <b class="calibre4">hydralazine</b>, penicillamine, minocycline, INH, methyldopa, quinidine, chlorpromazine, diltiazem, <b class="calibre4">anti-TNF</b> (esp. infliximab), interferons</p>
<p class="bl"><span class="sbl">•</span> Abrupt onset; generally mild disease with arthritis, serositis, skin disease; renal dx, malar and discoid rash rare; prevalence ♀:♂ = 1:1</p>
<p class="bl"><span class="sbl">•</span> ⊕ Anti-histone (95%) (may be ⊖ in anti-TNF); ⊖ anti-ds-DNA (often ⊕ in anti-TNF cases, even w/o manifestations of DLE) &amp; ⊖ anti-Sm; normal complement levels</p>
<p class="bl"><span class="sbl">•</span> Usually reversible w/in 4–6 wk after stopping medication</p>
<h2 class="ct"><a id="h107" class="calibre7"></a><a id="page_8-17" class="calibre7"></a><a href="part0002.html#rh118" class="calibre7">VASCULITIS</a></h2>
<p class="h">O<small class="calibre30">VERVIEW</small></p>
<p class="bl"><span class="sbl">•</span> Inflammation w/in blood vessel walls causing end-organ damage often a/w systemic sx; may be primary or secondary (eg, infection, malignancy) in etiology</p>
<p class="bl"><span class="sbl">•</span> Classified by size of <i class="calibre3">predominant</i> vessel affected <span class="s1r">(<i class="calibre3">Arthritis Rheum</i> 2013;65:1)</span>; overlap of vessel size affected is common</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations based on size of vessels involved; constitutional sx (low-grade fever, fatigue, weight loss, myalgias, anorexia) common to all</p>
<p class="imagef"><img src="../images/00130.jpeg" alt="" class="calibre2"/></p>
<p class="fn">TAK, Takayasu’s arteritis; GCA, giant cell arteritis; PAN, polyarteritis nodosa; ANCA-assoc. is GPA, EGPA, &amp; MPA; IC, immune complex small-vessel vasculitis (eg, HSP, cryoglobulinemia); GN, glomerulonephritis.</p>
<p class="h">L<small class="calibre30">ARGE</small>-V<small class="calibre30">ESSEL</small> V<small class="calibre30">ASCULITIS</small></p>
<p class="h2a">Takayasu’s arteritis <span class="s">(“pulseless disease”)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arteritis of aorta and its branches</b> → <b class="calibre4">stenosis/aneurysm</b> → claudication; onset &lt;50 y</p>
<p class="bl"><span class="sbl">•</span> Pattern of involvement: aorta and branches; most often <b class="calibre4">subclavian</b> and <b class="calibre4">innominate arteries</b> (&gt;90%), as well as carotid, coronary, renal, pulmonary (~50%)</p>
<p class="bl"><span class="sbl">•</span> Epidemiology: most common in <b class="calibre4">Asia;</b> ♀:♂ ~9:1; <b class="calibre4">age</b> &lt;<b class="calibre4">50 y</b></p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations and physical findings <span class="s1r">(<i class="calibre3">Circ</i> 2015;132:1701)</span></p>
<p class="bl1">Systemic inflamm with <b class="calibre4">fever</b>, <b class="calibre4">arthralgias</b>, wt loss</p>
<p class="bl1">Vessel inflamm w/ pain &amp; tenderness, ↓ <b class="calibre4">&amp; unequal pulses/BPs in extremities</b>, <b class="calibre4">bruits</b>, limb claudication, renovascular HTN (&gt;50%), neurogenic syncope; Ao aneurysm ± AI</p>
<p class="bl1">“Burnt out” or fibrotic period (eg, vascular stenosis)</p>
<p class="bl"><span class="sbl">•</span> Dx studies: ↑ ESR (75%), CRP; <b class="calibre4">arteriography</b> (MRA, CTA) → occlusion, stenosis, irregularity, and aneurysms; carotid U/S Doppler studies; PET-CT; <b class="calibre4">pathology</b> → focal panarteritis, cellular infiltrate with <i class="calibre3">granulomas</i> and giant cells (bx not required for dx)</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">steroids</b> ± MTX or AZA; anti-TNF (2<sup class="calibre15">nd</sup> line, <i class="calibre3">Autoimmun Rev</i> 2012;11:678); anti-IL-6 ? effective <span class="s1r">(<i class="calibre3">J Autoimmun</i> 2018;91:55)</span>; ASA; surgical/endovascular revasc <span class="s1r">(<i class="calibre3">Circ</i> 2008;69:70)</span></p>
<p class="bl"><span class="sbl">•</span> Monitoring: MRA or PET-CT <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2012;64:866)</span>; ESR/CRP <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2009;68:318)</span></p>
<p class="h2a">Giant cell arteritis (GCA) <span class="s">(<i class="calibre3">JAMA</i> 2016;315:2442)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Granulomatous arteritis of aorta/branches</b> w/ predilection for <b class="calibre4">temporal artery</b></p>
<p class="bl"><span class="sbl">•</span> Pattern of involvement: <b class="calibre4">extracranial branches of carotid artery</b>, esp. temporal artery (thus also called <b class="calibre4">temporal arteritis</b>); aorta and/or its branches in 10–80%</p>
<p class="bl"><span class="sbl">•</span> 90% of Pts w/ GCA are &gt;60 y, peak incidence at 70–80 y, extremely rare &lt;50 y; ♀:♂ = 3:1</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:50)</span></p>
<p class="bl1">Constitutional sx: <b class="calibre4">fevers</b>, fatigue, wt loss</p>
<p class="bl1"><b class="calibre4">Temporal artery (TA)</b> → <b class="calibre4">headache, tender TAs</b> and scalp, absent TA pulse</p>
<p class="bl1">Ophthalmic artery (20%) → optic neuropathy, diplopia, amaurosis fugax, blindness</p>
<p class="bl1">Facial arteries → <b class="calibre4">jaw claudication</b></p>
<p class="bl1">Large vessel vasculitis → intermittent claudication of extremities; thoracic aorta aneurysm</p>
<p class="bl1"><b class="calibre4">Strong association w/ PMR</b>; ~50% of Pts w/ GCA ultimately received PMR diagnosis</p>
<p class="bl"><span class="sbl">•</span> Dx studies: ↑ <b class="calibre4">ESR</b> (Se 84%, Sp 30%), ↑ CRP (Se 86%, Sp 30%), anemia</p>
<p class="bl1"><b class="calibre4">temporal artery bx</b> <i class="calibre3">whenever GCA suspected</i> (Se ≤85%); 1–2 cm ± bilat to ↑ yield (3– 7% discordance) <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2009;68:318)</span> → vasculitis &amp; <i class="calibre3">granulomas</i></p>
<p class="bl1">if suspect aortitis or lg-vessel involvement (BP Δ or bruits) → MRI/MRA or PET-CT</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">steroids</b>: <i class="calibre3">do not await bx/path results to begin!</i> Have at least 2 wk to bx w/o Δ results. Prednisone 40–60 mg/d w/ <i class="calibre3">slow</i> taper, ASA daily; consider IV steroid pulse if vision <a id="page_8-18" class="calibre1"></a>threatened. Adding tocilizumab helps achieve sustained remission <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:317)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polymyalgia rheumatica</b> <span class="s1r">(<i class="calibre3">JAMA</i> 2016;315:2442; <i class="calibre3">Lancet</i> 2017;390:1700)</span></p>
<p class="bl1">Seen in 50% of GCA Pts; 15% of Pts w/ PMR develop GCA</p>
<p class="bl1">Age ≥50 y; ESR &gt;40 mm/h (and/or ↑ CRP); <i class="calibre3">bilateral</i> <b class="calibre4"><i class="calibre3">pain &amp; morning stiffness</i></b> (&gt;30 min), involving 2 of 3 areas: neck or torso, shoulders or prox. arms, hips or prox. thighs; nighttime pain; ± subdeltoid bursitis on U/S; exclude other causes of sx (eg, RA); nl CK</p>
<p class="bl1">Rx: pred 12.5–25 mg/d; if clinical improvement, initiate slow taper. If no improvement, ↑ dose. Consider MTX if at high risk for steroid side effects <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2015;74:1799)</span>.</p>
<p class="bl"><span class="sbl">•</span> Follow clinical status &amp; ESR/CRP <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2009;68:318)</span>; ~1/3 relapse over 2 y <span class="s">(<i class="calibre3">J Rheum</i> 2015;42:1213)</span></p>
<p class="h">M<small class="calibre30">EDIUM</small>-V<small class="calibre30">ESSEL</small> V<small class="calibre30">ASCULITIS</small></p>
<p class="h2a">Polyarteritis nodosa <span class="s">(“classic” PAN) <span class="tfont1">(<i class="calibre3">Arth Rheum</i> 2010;62:616)</span></span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Necrotizing nongranulomatous vasculitis of medium and small arteries</b> (w/ muscular media) w/o glomerulonephritis or capillary involvement (ie, no DAH), not a/w ANCA</p>
<p class="bl"><span class="sbl">•</span> Epidemiology: ♂ &gt; ♀; average age of onset ~50 y; 1° vs. 2° (<b class="calibre4">HBV</b> &gt; HCV; ~10%)</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations</p>
<p class="bl1">Constitutional sx (80%): wt loss, <b class="calibre4">fever</b>, fatigue</p>
<p class="bl1">Neuro (79%): <b class="calibre4">mononeuritis multiplex</b>, peripheral neuropathies, stroke</p>
<p class="bl1">Musculoskeletal (64%): <b class="calibre4">extremity pain</b>, <b class="calibre4">myalgias</b>, arthralgias, arthritis</p>
<p class="bl1">Renal (51%): <b class="calibre4">HTN</b>, hematuria, proteinuria, renal failure, <i class="calibre3">glomerulonephritis unusual</i></p>
<p class="bl1">GI (38%): <b class="calibre4">abd pain</b>, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain</p>
<p class="bl1">Skin (50%): <b class="calibre4">livedo reticularis</b>, purpura, nodules, ulcers, Raynaud’s</p>
<p class="bl1">Ophthalmic (9%): retinal vasculitis, retinal exudates, conjunctivitis, uveitis</p>
<p class="bl1">Cardiac (22%): coronary arteritis, cardiomyopathy, pericarditis</p>
<p class="bl1">Pulmonary: rare; <b class="calibre4">if lung involvement, suspect other vasculitis</b></p>
<p class="bl"><span class="sbl">•</span> Dx studies: ↑ ESR/CRP, ANCA, HBV testing, ↓ C3/C4 if HBV-associated</p>
<p class="bl1"><b class="calibre4">Angiogram</b> (mesenteric or renal vessels) → <b class="calibre4">microaneurysms</b> &amp; focal vessel narrowing</p>
<p class="bl1">CTA may be adequate to make dx, but conventional angiogram is most sensitive</p>
<p class="bl1"><b class="calibre4">Biopsy</b> (sural nerve, skin, or affected organ) → vasculitis of small- and medium-vessel arteries with fibrinoid necrosis <i class="calibre3">without granulomas</i></p>
<p class="bl"><span class="sbl">•</span> Rx: based on severity; <b class="calibre4">steroids</b> ± DMARD (eg, MTX or CYC); antivirals if a/w HBV</p>
<p class="h">ANCA-A<small class="calibre30">SSOCIATED</small> S<small class="calibre30">MALL</small>-V<small class="calibre30">ESSEL</small> V<small class="calibre30">ASCULITIS</small></p>
<p class="cst"><i class="calibre3">Microvascular vasculitis (eg, capillaries, postcapillary venules, &amp; arterioles)</i></p>
<p class="imagef"><img src="../images/00131.jpeg" alt="" class="calibre2"/></p>
<p class="fn1"><sup class="calibre35">a</sup>Predominant ANCA type; either p- or c-ANCA can be seen in all three diseases <span class="tfont1">(<i class="calibre3">NEJM</i> 2012;367:214)</span>.</p>
<p class="fn"><sup class="calibre35">b</sup>GPA is formerly Wegener’s granulomatosis and EGPA is formerly Churg-Strauss.</p>
<p class="h2a">Differential diagnosis of ANCA <span class="s">(<i class="calibre3">Lancet</i> 2006;368:404)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">anti-PR3 (c-ANCA):</b> GPA, EGPA, microscopic polyangiitis (rarely), levamisole (contaminant in cocaine) both c- &amp; p-ANCA ⊕</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">anti-MPO (p-ANCA):</b> microscopic polyangiitis, EGPA, GPA, drug-induced vasculitis, nonvasculitic rheumatic dis., levamisole (contaminant in cocaine) both c- &amp; p-ANCA ⊕</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Atypical ANCA patterns:</b> drug-induced vasculitis, nonvasculitic rheumatic diseases,</p>
<p class="bl1">ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis</p>
<p class="h2a">Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Necrotizing granulomatous systemic vasculitis</b> frequently affecting nose, sinuses and/or upper respiratory tract in addition to kidneys, lungs, etc.</p>
<p class="bl"><span class="sbl">•</span> Epidemiology: any age, but ↑ incidence in young and middle-aged adults; ♂=♀</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations</p>
<p class="bl1">Constitutional: fever, fatigue, malaise, anorexia, <b class="calibre4">unexplained wt loss</b></p>
<p class="bl1"><b class="calibre4">Respiratory</b> (90%): <span class="underline">Upper</span>: <b class="calibre4">recurrent sinusitis</b>, rhinitis, oral/nasal ulcers, <b class="calibre4">nasal crusting</b>, <b class="calibre4">saddle-nose deformity</b>, otitis, hearing loss, subglottic stenosis;</p>
<p class="bl2"><span class="underline">Lower</span><i class="calibre3">:</i> <b class="calibre4">pulm. infiltrates</b>, <b class="calibre4">nodules</b>, <b class="calibre4">pulm. hemorrhage</b>, hemoptysis, pleurisy</p>
<p class="bl1"><b class="calibre4">Renal</b> (80%): <b class="calibre4">RPGN</b> (pauci-immune), RBC casts, dysmorphic RBCs, hematuria</p>
<p class="bl1">Ocular (50%): episcleritis, scleritis, uveitis, orbital granulomas → proptosis, corneal ulcer</p>
<p class="bl1">Neurologic: cranial and peripheral neuropathies, <b class="calibre4">mononeuritis multiplex</b></p>
<p class="bl1"><a id="page_8-19" class="calibre1"></a>Skin (50%): palpable purpura, livedo reticularis</p>
<p class="bl1">Hematologic: ↑ incidence DVT/PE (20×) when disease active <span class="s1r">(<i class="calibre3">Ann Intern Med</i> 2005;142:620)</span></p>
<p class="bl"><span class="sbl">•</span> Dx studies: <b class="calibre4">90%</b> ⊕ <b class="calibre4">ANCA</b> (80% PR3, 20% MPO), less Se in limited upper-airway disease</p>
<p class="bl1">CXR or CT → nodules, infiltrates, cavities; sinus CT → sinusitis ± bone erosions</p>
<p class="bl1">↑ BUN &amp; Cr, proteinuria, hematuria; sediment w/ RBC casts, dysmorphic RBCs</p>
<p class="bl1">Biopsy → necrotizing granulomatous inflammation of arterioles, capillaries, veins</p>
<p class="bl"><span class="sbl">•</span> Treatment: assess disease severity with BVAS/WG score <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2001;44:912)</span></p>
<p class="bl1"><b class="calibre4">Mild disease</b> (no end-organ dysfxn; BVAS 0-3): <b class="calibre4">MTX</b> + <b class="calibre4">steroids</b> <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2012;64:3472)</span></p>
<p class="bl1"><b class="calibre4">Severe disease</b> (end-organ damage incl. pulm hemorrhage, RPGN etc.; BVAS &gt;3):</p>
<p class="bl2"><i class="calibre3">Induction:</i> [<b class="calibre4">RTX</b> 375 MG/m<sup class="calibre15">2</sup>/wk × 4 wk <i class="calibre3">or</i> <b class="calibre4">CYC</b> 2 mg/kg/d × 3–6 mo or pulse 15 mg/kg q2–3wk] + <b class="calibre4">steroids</b> 1 g IV × 3 d → 1–2 mg/kg/d <span class="s1r">(<i class="calibre3">NEJM</i> 2005;352:351, 2010;363:211, &amp; 2013;369:417; <i class="calibre3">Annals</i> 2009;150:670; <i class="calibre3">Ann Rheum Dis</i> 2015;74:1178)</span></p>
<p class="bl2">If RPGN: ± plasma exchange to ? ↓ risk of ESRD <span class="s1r">(<i class="calibre3">Am J Kidney Dis</i> 2011;57:566)</span></p>
<p class="bl2"><i class="calibre3">Maintenance:</i> RTX q6mo superior to AZA or watchful waiting <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2012;64:3760; <i class="calibre3">NEJM</i> 2014;371:1771)</span></p>
<p class="bl1"><b class="calibre4">Relapse:</b> mild → steroids ± MTX or AZA; severe → reinduce w/ steroids + RTX or CYC</p>
<p class="bl1">↑ ANCA w/o clinical evidence of flare should <i class="calibre3">not</i> prompt Δ Rx <span class="s1r">(<i class="calibre3">Annals</i> 2007;147:611)</span></p>
<p class="h2a">Microscopic polyangiitis (MPA) <span class="s">(<i class="calibre3">Rheum Dis Clin North Am</i> 2010;36:545)</span></p>
<p class="bl"><span class="sbl">•</span> Similar to GPA, but <b class="calibre4">w/o ENT/airway involvement &amp; nongranulomatous</b></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: ♂ &gt; ♀; avg onset 50–60 y</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: similar to GPA <i class="calibre3">w/o upper respiratory involvement;</i> <b class="calibre4">Renal</b> (80–100%): glomerulonephritis <b class="calibre4">Pulmonary</b> (25–50%): pulmonary capillary alveolitis, pulmonary fibrosis Constitutional and neuro sx similar to GPA; skin lesions (eg, palpable purpura) in 30–60%</p>
<p class="bl"><span class="sbl">•</span> Dx studies: <b class="calibre4">70%</b> ⊕ <b class="calibre4">ANCA</b> (almost all anti-MPO)</p>
<p class="bl1">biopsy → necrotizing, <b class="calibre4">nongranulomatous</b> inflammation of small vessels, pauci-immune (minimal deposition of complement or Ig; contrast w/ HSP, cryoglobulinemia, etc.)</p>
<p class="bl1">urine sediment and CXR findings similar to those seen in GPA</p>
<p class="bl"><span class="sbl">•</span> Treatment: as for GPA; ↓ relapse rate compared to GPA</p>
<p class="h2a">Eosinophilic granulomatosis with polyangiitis <span class="s">(EGPA, formerly Churg-Strauss)</span></p>
<p class="bl"><span class="sbl">•</span> Similar to GPA w/ more frequent <b class="calibre4">cardiac involvement</b>, a/w <b class="calibre4">asthma</b> and <b class="calibre4">eosinophilia</b></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: rare; can present at any age (typically 30–40 y); a/w HLA-DRB4</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations <span class="s1r">(<i class="calibre3">Curr Rheumatol Rep</i> 2011;13:489)</span></p>
<p class="bl1">Initial sx: <b class="calibre4">asthma</b>, sinusitis, allergic rhinitis (new asthma in adult raises suspicion)</p>
<p class="bl1">Eosinophilic infiltrative disease: transient <b class="calibre4">pulm infiltrates</b>, gastroenteritis, or esophagitis</p>
<p class="bl1">Systemic small-vessel vasculitis: <b class="calibre4">neuropathy</b> (mononeuritis multiplex), renal (glomerulonephritis), skin (palpable purpura, petechial, nodules)</p>
<p class="bl1"><b class="calibre4">Cardiac:</b> coronary arteritis, myocarditis, CHF, valvular insufficiency <span class="s1r">(<i class="calibre3">Medicine</i> 2009;88:236)</span></p>
<p class="bl"><span class="sbl">•</span> Dx studies: 50% ⊕ ANCA (MPO &gt; PR3), <b class="calibre4">eosinophilia</b> (5–10 k/µL, 80–100%),</p>
<p class="bl1">biopsy → microgranulomas, fibrinoid necrosis, and thrombosis of small arteries and veins with eosinophilic infiltrates</p>
<p class="bl"><span class="sbl">•</span> Treatment: high-dose <b class="calibre4">steroids</b> + CYC (if severe); anti-IL5 (mepolizumab) for refractory/relapsing <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1921)</span></p>
<p class="h2a">Renal-limited vasculitis</p>
<p class="bl"><span class="sbl">•</span> Small vessel pauci-immune vasculitis causing RPGN w/o other organ involvement</p>
<p class="bl"><span class="sbl">•</span> Dx studies: 80% ⊕ ANCA (MPO &gt; PR3); biopsy with pauci-immune GN ± granulomas</p>
<p class="bl"><span class="sbl">•</span> Treatment identical to that for GPA/MPA</p>
<p class="h">I<small class="calibre30">MMUNE</small> C<small class="calibre30">OMPLEX</small> (IC)–A<small class="calibre30">SSOCIATED</small> S<small class="calibre30">MALL</small>-V<small class="calibre30">ESSEL</small> V<small class="calibre30">ASCULITIS</small></p>
<p class="h2a">Henoch-Schönlein purpura (HSP)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IgA-mediated</b> vasculitis w/ predilection for <b class="calibre4">skin</b>, <b class="calibre4">GI tract</b>, and <b class="calibre4">kidneys</b></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: ♂ &gt; ♀, children &gt; adults, onset in winter &gt; summer</p>
<p class="bl"><span class="sbl">•</span> May develop after upper respiratory tract infection (esp. <i class="calibre3">Strep</i>) or drug exposure</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations</p>
<p class="bl1"><b class="calibre4">Palpable purpura</b> on extensor surfaces (lower extremity first) &amp; buttocks</p>
<p class="bl1"><b class="calibre4">Polyarthralgias</b> (nondeforming) esp. involving hips, knees, &amp; ankles</p>
<p class="bl1">Colicky <b class="calibre4">abdominal pain</b> ± GIB or intussusception</p>
<p class="bl1">Nephritis ranging from <b class="calibre4">microscopic hematuria</b> &amp; proteinuria to ESRD</p>
<p class="bl"><span class="sbl">•</span> Dx studies: <b class="calibre4">skin bx w/ immunofluorescence</b> → <b class="calibre4">leukocytoclastic vasculitis</b> w/ <b class="calibre4">IgA</b></p>
<p class="bl1">and <b class="calibre4">C3</b> deposition in vessel wall; renal bx → mesangial IgA deposition</p>
<p class="bl"><span class="sbl">•</span> Treatment: often self-limiting over 4 wk; steroids ± DMARDs for renal or severe disease</p>
<p class="h2a"><a id="page_8-20" class="calibre1"></a>Connective tissue disease–associated vasculitis</p>
<p class="bl"><span class="sbl">•</span> Small-vessel vasculitis a/w <b class="calibre4">RA</b>, <b class="calibre4">SLE</b> or <b class="calibre4">Sjögren’s syndrome</b></p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations</p>
<p class="bl1">Distal arteritis: digital ischemia, livedo reticularis, palpable purpura, cutaneous ulceration</p>
<p class="bl1">Visceral arteritis: pericarditis and mesenteric ischemia</p>
<p class="bl1">Peripheral neuropathy</p>
<p class="bl"><span class="sbl">•</span> Dx studies: skin/sural nerve bx, EMG, angiography; ↓ C′ in SLE; ⊕ RF or anti-CCP in RA</p>
<p class="bl"><span class="sbl">•</span> Treatment: steroids, cyclophosphamide, MTX (other DMARDs)</p>
<p class="h2a">Cutaneous leukocytoclastic angiitis</p>
<p class="bl"><span class="sbl">•</span> Most common type of vasculitis; heterogeneous group of clinical syndromes due to <b class="calibre4">IC deposition</b> in capillaries, venules, and arterioles; includes <b class="calibre4"><i class="calibre3">hypersensitivity vasculitis</i></b></p>
<p class="bl"><span class="sbl">•</span> Etiologies</p>
<p class="bl1">Drugs: PCN, ASA, amphetamines, levamisole, thiazides, chemicals, immunizations, etc.</p>
<p class="bl1">Infections: <i class="calibre3">Strep</i>, <i class="calibre3">Staph</i>, endocarditis, TB, hepatitis</p>
<p class="bl1">Malignancy (paraneoplastic)</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: abrupt onset of <b class="calibre4">palpable purpura</b> and <b class="calibre4">transient arthralgias</b> after exposure to the offending agent; visceral involvement rare but can be severe</p>
<p class="bl"><span class="sbl">•</span> Dx studies: ↑ ESR, ↓ complement levels, eosinophilia; ✔ U/A; <b class="calibre4">skin biopsy</b> → leukocytoclastic vasculitis <b class="calibre4"><i class="calibre3">w/o IgA deposition</i></b> in skin (to distinguish from HSP)<i class="calibre3">;</i> if etiology not clear, consider ANCA, cryoglobulins, hepatitis serologies, ANA, RF</p>
<p class="bl"><span class="sbl">•</span> Treatment: withdrawal of offending agent ± rapid prednisone taper</p>
<p class="h2a">Behçet’s syndrome <span class="s">(<i class="calibre3">Curr Rheum Opin</i> 2010;12:429)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systemic vasculitis</b> affecting all vessel sizes, a/w painful <b class="calibre4">oral and/or genital ulcers</b></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: usually young adults (25–35 y); a/w HLA-B51 in areas of highest prevalence on the old Silk Road (Turkey, Middle East, and other Asian countries)</p>
<p class="bl"><span class="sbl">•</span> Classification criteria (#1 + ≥2 others is 91% Se &amp; 96% Sp; <i class="calibre3">Lancet</i> 1990;335:1078)</p>
<p class="bl1">1. Recurrent <b class="calibre4">oral aphthous ulceration</b> (≥3× in 1 y, usually 1<sup class="calibre15">st</sup> manifestation)</p>
<p class="bl1">2. Recurrent <b class="calibre4">genital ulceration</b> (labia in females, scrotum in males)</p>
<p class="bl1">3. <b class="calibre4">Eye lesions:</b> uveitis, scleritis, retinal vasculitis, optic neuritis; <i class="calibre3">may threaten vision</i></p>
<p class="bl1">4. <b class="calibre4">Skin lesions:</b> pustules, papules, folliculitis, erythema nodosum (scarring)</p>
<p class="bl1">5. ⊕ pathergy test (prick forearm w/ sterile needle → pustule) (not sensitive in Caucasians)</p>
<p class="bl"><span class="sbl">•</span> Other clinical manifestations: most recur but are not chronic</p>
<p class="bl1">Arthritis: mild, ± symmetric, nondestructive, involving knees and ankles</p>
<p class="bl1">Neurologic: usually involvement of midbrain parenchyma; peripheral neuropathy rare</p>
<p class="bl1">Vascular: superficial or deep vein thrombosis (25%); arterial stenosis, occlusion, and aneurysm can also occur; low incidence of thromboembolism</p>
<p class="bl"><span class="sbl">•</span> Dx studies: ↑ ESR/CRP; ulcer swab to r/o HSV; ulcer bx nonspecific; ophtho eval if sx</p>
<p class="bl"><span class="sbl">•</span> Treatment <span class="s1r">(<i class="calibre3">Rheumatology</i> 2007;46:736; <i class="calibre3">Ann Rheum Dis</i> 2008;67:1656 &amp; 2009;68:1528)</span></p>
<p class="bl1">Mucocutaneous:</p>
<p class="bl2">Mild: <b class="calibre4">topical steroids</b>, <b class="calibre4">colchicine</b> (esp. for erythema nodosum), dapsone, apremilast (PDE-4 inhib) for oral ulcers and ? genital ulcers <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1510)</span>,</p>
<p class="bl2">Severe: oral steroids, steroid-sparing agents</p>
<p class="bl1">Arthritis: NSAIDs, colchicine, steroids, steroid-sparing agents</p>
<p class="bl1">Ocular: <b class="calibre4">topical and/or systemic steroids</b> ± steroid-sparing agents</p>
<p class="bl1">Steroid-sparing: AZA, anti-TNF, CYC (large vessel and CNS ds), CsA, MTX, IFNα-2A,</p>
<p class="bl1">Venous thrombosis: steroids and anticoagulation (careful if aneurysm present)</p>
<h2 class="ct"><a id="h108" class="calibre7"></a><a href="part0002.html#rh119" class="calibre7">IGG4-RELATED DISEASE</a></h2>
<p class="h2a">Definition &amp; etiology <span class="s">(<i class="calibre3">NEJM</i> 2012;366:539; <i class="calibre3">Ann Rev Pathol</i> 2014;9:315)</span></p>
<p class="bl"><span class="sbl">•</span> Characterized by tumor-like inflammatory lesions that can affect nearly any organ</p>
<p class="bl"><span class="sbl">•</span> Etiology unclear: ? autoimmune; unclear role of IgG4 Ab; Pt may have h/o atopy</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2015;385:1460; <i class="calibre3">Arth Rheum</i> 2015;67:2466)</span></p>
<p class="bl"><span class="sbl">•</span> Commonly pancreatitis, aortitis, cholangitis, sialadenitis, thyroiditis, orbital myositis ± pseudotumor, retroperitoneal fibrosis</p>
<p class="bl"><span class="sbl">•</span> Multiple lesions may be present synchronously or metachronously</p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2015;74:1 &amp; 14)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biopsy</b> w/ specific histopathology &amp; immunohistochemistry findings: lymphoplasmacytic infiltrate w/ significant IgG4+ plasma cell infiltrate, fibrosis, obliterative phlebitis</p>
<p class="bl"><span class="sbl">•</span> ↑ serum IgG4 (Se 90%, Sp 60%); <i class="calibre3">not specific</i> seen in GPA, bronchiectasis <span class="s">(<i class="calibre3">Ann Rheum Dis</i> 2014;74:14)</span></p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Arth Rheum</i> 2015;67:1688)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prednisone</b> vs. rituximab <span class="s1r">(<i class="calibre3">Ann Rheum Dis</i> 2015;74:1171)</span></p>
<h2 class="ct"><a id="h109" class="calibre7"></a><a id="page_8-21" class="calibre7"></a><a href="part0002.html#rh120" class="calibre7">CRYOGLOBULINEMIA</a></h2>
<p class="h2a">Definition &amp; types <span class="s">(<i class="calibre3">Lancet</i> 2012;379:348; <i class="calibre3">Oncology</i> 2013;37:1098)</span></p>
<p class="bl"><span class="sbl">•</span> Cryo<span class="underline">globulins</span>: proteins that <b class="calibre4">precipitate</b> from <i class="calibre3">serum or plasma</i> <b class="calibre4">on exposure to cold and redissolve on rewarming</b>, characterized by their composition; a/w chronic immune stimulation and/or lymphoproliferation</p>
<p class="bl"><span class="sbl">•</span> Distinguish from <i class="calibre3">cryo<span class="underline">fibrinogenemia</span></i> = proteins (eg, fibrin, fibrinogen) that precipitate only from <i class="calibre3">plasma;</i> found in autoimmune dis, malignancies, infxns; unclear clinical significance</p>
<p class="image1"><img src="../images/00132.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> Hematologic diseases</p>
<p class="bl1">Type I: multiple myeloma, MGUS, Waldenström’s, chronic lymphocytic leukemia</p>
<p class="bl1">Type II: B-cell lymphomas, solid-organ malignancies</p>
<p class="bl"><span class="sbl">•</span> Infections (types II &amp; III): viral (<b class="calibre4">HCV</b> [&gt;80% RNA ⊕], HBV, HIV, HAV, EBV, CMV), bacterial (endocarditis, strep, etc.), fungal (coccidiomycosis, etc.), parasitic (malaria, amoebiasis)</p>
<p class="bl"><span class="sbl">•</span> Autoimmune syndromes (type III &gt; II): <b class="calibre4">Sjögren’s syndrome</b>, SLE, RA, PAN</p>
<p class="bl"><span class="sbl">•</span> Renal transplant recipients <span class="s1r">(<i class="calibre3">Clin Nephrol</i> 2008;69:239)</span></p>
<p class="bl"><span class="sbl">•</span> Essential (idiopathic) in 10% of cases</p>
<p class="h2a">Pathophysiology</p>
<p class="bl"><span class="sbl">•</span> Type I: cryo precipitation in microcirculation → <b class="calibre4">hyperviscosity</b> &amp; <b class="calibre4">vascular occlusion</b></p>
<p class="bl"><span class="sbl">•</span> Types II/III: defective/insufficient immune complex (IC) clearance → IC-mediated inflammation of blood vessels w/ complement activation → <b class="calibre4">vasculitis</b></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Most patients with circulating cryoglobulins are asx</p>
<p class="bl"><span class="sbl">•</span> Type I: hyperviscosity (cold worsens sx) → H/A, visual disturbance, livedo, digital ischemia</p>
<p class="bl"><span class="sbl">•</span> Type II/III: vasculitis (sx not affected by cold exposure)</p>
<p class="bl1">“Meltzer’s triad” (purpura, arthralgias, weakness) seen in 25–30% of Pts</p>
<p class="bl1">General: <b class="calibre4">weakness</b>, low-grade fever</p>
<p class="bl1">Dermatologic (54–80%): lower extremity <b class="calibre4">purpura</b>, livedo reticularis, leg ulcers</p>
<p class="bl1">Joint (44–70%): symmetric, migratory <b class="calibre4">arthralgias</b> of small or medium joints</p>
<p class="bl1">Renal (50%): <b class="calibre4">glomerulonephritis</b> (proteinuria, hematuria, ARF, HTN, edema)</p>
<p class="bl1">Neurologic (17–60%): <b class="calibre4">peripheral neuropathy</b> (polyneuropathy &gt; mononeuritis multiplex)</p>
<p class="bl1">Hematologic: anemia, thrombocytopenia, ↑ risk of B-cell lymphoma</p>
<p class="bl1">GI (5%): abdominal pain, hepatosplenomegaly, abnormal LFTs</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> ✔ Cryoglobulins; must keep blood <i class="calibre3">warmed to 37</i>°<i class="calibre3">C at all times</i> en route to lab; early cooling causes false ⊖ cryoglobulin, loss of RF and ↓↓ complement</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Cryocrit</i> is quantification of cryoprotein, does not always correlate w/ disease activity</p>
<p class="bl"><span class="sbl">•</span> False ↑ in WBC or plt on automated CBC, due to cryoprecipitation</p>
<p class="bl"><span class="sbl">•</span> Type I: ✔ serum viscosity, symptomatic if ≥4.0 centipoise; complement levels normal</p>
<p class="bl"><span class="sbl">•</span> Type II: ↓ <b class="calibre4">C4 levels</b>, variable C3 levels, ↑ ESR, ⊕ rheumatoid factor (RF)</p>
<p class="bl1">✔ <b class="calibre4">HCV, HBV, &amp; HIV serologies</b> in all Pts w/ mixed cryoglobulinemia</p>
<p class="bl1">Bx of affected tissue: hyaline thrombi; vasculitis w/ mixed inflammatory infiltrates of small vessels; leukocytoclastic vasculitis in purpuric lesions</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Blood</i> 2012;119:5996; <i class="calibre3">Medicine</i> 2013;92:61)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treat underlying disorder:</b></p>
<p class="bl1">Lymphoproliferative disease: chemotherapy and/or radiation</p>
<p class="bl1">HCV: antivirals ± immunosuppression for severe disease <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:1035)</span></p>
<p class="bl1">Connective tissue–related disease: DMARD/steroids ± rituximab</p>
<p class="bl"><span class="sbl">•</span> Type I: plasma exchange if hyperviscosity; steroids, alkylating agents, rituximab, chemo</p>
<p class="bl"><span class="sbl">•</span> Type II: NSAIDs for control of mild symptoms for Pts w/ normal renal function.</p>
<p class="bl1">Rituximab or cyclophosphamide for major organ involvement. For mixed cryo, plasmapheresis or plasma exchange only in severe, life-threatening disease.</p>
<h2 class="ct"><a id="h110" class="calibre7"></a><a id="page_8-22" class="calibre7"></a><a href="part0002.html#rh121" class="calibre7">AMYLOIDOSIS</a></h2>
<p class="cst"><i class="calibre3">Deposition of misfolded and insoluble fibrous proteins in normal organs and tissues</i></p>
<p class="imagef"><img src="../images/00133.jpeg" alt="" class="calibre2"/></p>
<p class="fn">TTR, transthyretin (prealbumin). Adapted from <i class="calibre3">NEJM</i> 1997;337:898; 2003;349:583; &amp; 2007;356:2361.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre24"/>
<col class="calibre33"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc">Clinical Manifestations of Amyloidosis <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">6;387:264</span><span class="tfont1">1</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">System</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Manifestations</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Amyloid</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal</b></p></td>
<td class="bg0-br"><p class="tab">Proteinuria or nephrotic syndrome</p></td>
<td class="bg0-b"><p class="tabc">AL, AA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiac</b></p></td>
<td class="bg0-br"><p class="tab">CMP (either restrictive or dilated); orthostatic hypoTN</p>
<p class="tab">↓ QRS amplitude, conduction abnormalities, AF</p></td>
<td class="bg0-b"><p class="tabc">AL, hereditary, senile</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GI</b></p></td>
<td class="bg0-br"><p class="tab">Diarrhea, malabsorption, protein loss</p>
<p class="tab">Ulceration, hemorrhage, obstruction</p>
<p class="tab">Macroglossia → dysphonia and dysphagia</p></td>
<td class="bg0-b"><p class="tabc">All systemic</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Neurologic</b></p></td>
<td class="bg0-br"><p class="tab">Peripheral neuropathy with painful paresthesias</p>
<p class="tab">Autonomic neuro → impotence, dysmotility, ↓ BP</p>
<p class="tab">Carpal tunnel syndrome</p></td>
<td class="bg0-b"><p class="tabc">Hereditary, AL, organ-specific, Aβ<sub class="calibre13">2</sub>M</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cutaneous</b></p></td>
<td class="bg0-br"><p class="tab">Waxy, nonpruritic papules; periorbital ecchymoses</p>
<p class="tab">“Pinch purpura” = skin bleeds with minimal trauma</p></td>
<td class="bg0-b"><p class="tabc">AL</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hepatic &amp; splenic</b></p></td>
<td class="bg0-br"><p class="tab">Hepatomegaly, usually <i class="calibre3">without</i> dysfunction</p>
<p class="tab">Splenomegaly, usually <i class="calibre3">without</i> leukopenia or anemia</p></td>
<td class="bg0-b"><p class="tabc">All systemic</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Endocrine</b></p></td>
<td class="bg0-br"><p class="tab">Deposition with rare hormonal insufficiency</p></td>
<td class="bg0-b"><p class="tabc">Organ-specific</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Musculoskel</b></p></td>
<td class="bg0-br"><p class="tab">Arthralgias and arthritis (especially shoulder)</p></td>
<td class="bg0-b"><p class="tabc">AL, Aβ<sub class="calibre13">2</sub>M</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulmonary</b></p></td>
<td class="bg0-br"><p class="tab">Airway obstruction; pleural effusions</p></td>
<td class="bg0-b"><p class="tabc">AL, AA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Hematologic</b></p></td>
<td class="bg0-r"><p class="tab">Factor X deficiency</p></td>
<td class="bg"><p class="tabc">AL</p></td>
</tr>
</table>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Biopsy (abdominal SC fat pad, rectal, or affected tissue) → apple-green birefringence on <b class="calibre4">Congo red stain;</b> fat pad bx Se 60–85%, Sp 90–100%</p>
<p class="bl"><span class="sbl">•</span> If suspect AL → ✔ SIEP &amp; UIEP (↑ Se vs. SPEP &amp; UPEP) &amp; free light chains, ± BM bx</p>
<p class="bl"><span class="sbl">•</span> If suspect renal involvement ✔ U/A for proteinuria</p>
<p class="bl"><span class="sbl">•</span> If suspect cardiac involvement ✔ ECG (↓ voltage, conduction abnl), TTE (biventricular valve leaflet &amp; interatrial septum thickening), ↑ wall w/o ↑ volt has 75% Se, 95% Sp; MRI</p>
<p class="bl"><span class="sbl">•</span> Genetic testing for hereditary forms</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre59"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc">Treatment of Amyloidosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">AL</p></td>
<td class="bg0-b"><p class="tab">Limited involvement: high-dose <b class="calibre4">melphalan</b> → <b class="calibre4">auto HSCT</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">2007;357:</span><span class="tfont1">1</span><span class="tfont1">083)</span></p>
<p class="tabh">Not HSCT candidate: [low-dose melphalan + dexamethasone] or [cyclophosphamide + bortezomib + dexamethasone] <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;</span><span class="tfont1">1</span><span class="tfont1">26:6</span><span class="tfont1">1</span><span class="tfont1">2)</span></p>
<p class="tab">Relapsed: lenalidomide, thalidomide, or bortezomib <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">0;</span><span class="tfont1">11</span><span class="tfont1">6:</span><span class="tfont1">1</span><span class="tfont1">990 &amp; 20</span><span class="tfont1">1</span><span class="tfont1">4;</span><span class="tfont1">1</span><span class="tfont1">24:2498)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b3"><p class="tab">AA</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Rx underlying disease.</b> Colchicine for FMF, esp. to prevent renal disease.</p>
<p class="tab">? Anti-cytokine Rx (anakinra or tocilizumab) <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Clin Exp Rheumatol</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">5;33:46)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg3-r"><p class="tab">ATTR</p></td>
<td class="bg"><p class="tab">Liver Tx prevents further protein deposition <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Muscle Nerve</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">3;47:</span><span class="tfont1">1</span><span class="tfont1">57)</span></p>
<p class="tabh">↓ hepatic TTR production: siRNA (patisiran) or anti-sense oligo (inotersen) improve neuropathy <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;379:</span><span class="tfont1">11</span> <span class="tfont1">&amp; 22)</span></p>
<p class="tabh">Stabilize TTR tetramers (also useful for senile amyloidosis): tafamidis ↑ QoL &amp; ↓ CV hosp &amp; mortality <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;379:</span><span class="tfont1">1</span><span class="tfont1">007)</span></p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Clearance of amyloid by Ab against serum amyloid P under study <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:1106)</span></p>
<p class="bl"><span class="sbl">•</span> Cardiac involvement: diuretics; avoid dig, CCB, and vasodilators; ? ICD for 1° prevention</p>
<p class="bl"><span class="sbl">•</span> Heart, kidney, and liver Tx may be considered in those w/ advanced disease</p>
<p class="bl"><span class="sbl">•</span> Median survival: 12–18 mo for AL (~6 if cardiac); 11 y for AA; variable for others</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0012.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0014.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
